WO2020028722A1 - Biosynthetic platform for the production of cannabinoids and other prenylated compounds - Google Patents
Biosynthetic platform for the production of cannabinoids and other prenylated compounds Download PDFInfo
- Publication number
- WO2020028722A1 WO2020028722A1 PCT/US2019/044752 US2019044752W WO2020028722A1 WO 2020028722 A1 WO2020028722 A1 WO 2020028722A1 US 2019044752 W US2019044752 W US 2019044752W WO 2020028722 A1 WO2020028722 A1 WO 2020028722A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pathway
- seq
- sequence
- recombinant
- nphb
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 66
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 66
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 57
- 150000001875 compounds Chemical class 0.000 title claims description 25
- 229940065144 cannabinoids Drugs 0.000 title abstract description 39
- 230000001851 biosynthetic effect Effects 0.000 title description 6
- 102000004190 Enzymes Human genes 0.000 claims abstract description 131
- 108090000790 Enzymes Proteins 0.000 claims abstract description 131
- 238000006243 chemical reaction Methods 0.000 claims abstract description 105
- 230000037361 pathway Effects 0.000 claims abstract description 83
- 244000005700 microbiome Species 0.000 claims abstract description 62
- 230000013823 prenylation Effects 0.000 claims abstract description 23
- 239000002243 precursor Substances 0.000 claims abstract description 16
- SXFKFRRXJUJGSS-UHFFFAOYSA-N olivetolic acid Chemical compound CCCCCC1=CC(O)=CC(O)=C1C(O)=O SXFKFRRXJUJGSS-UHFFFAOYSA-N 0.000 claims description 72
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 claims description 60
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 60
- 230000035772 mutation Effects 0.000 claims description 58
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 claims description 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 49
- 239000000758 substrate Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 41
- 102000040430 polynucleotide Human genes 0.000 claims description 41
- 108091033319 polynucleotide Proteins 0.000 claims description 41
- 239000002157 polynucleotide Substances 0.000 claims description 41
- 150000001413 amino acids Chemical group 0.000 claims description 36
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 32
- FAVCTJGKHFHFHJ-GXDHUFHOSA-N 3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-propylbenzoic acid Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O FAVCTJGKHFHFHJ-GXDHUFHOSA-N 0.000 claims description 31
- FAVCTJGKHFHFHJ-UHFFFAOYSA-N CBGVA Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O FAVCTJGKHFHFHJ-UHFFFAOYSA-N 0.000 claims description 31
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 230000002255 enzymatic effect Effects 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 108010042687 Pyruvate Oxidase Proteins 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 21
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 230000001419 dependent effect Effects 0.000 claims description 18
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 16
- RIVVNGIVVYEIRS-UHFFFAOYSA-N Divaric acid Chemical compound CCCC1=CC(O)=CC(O)=C1C(O)=O RIVVNGIVVYEIRS-UHFFFAOYSA-N 0.000 claims description 15
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 15
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 15
- 101710088194 Dehydrogenase Proteins 0.000 claims description 13
- 102000005548 Hexokinase Human genes 0.000 claims description 12
- 108700040460 Hexokinases Proteins 0.000 claims description 12
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims description 12
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 claims description 10
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 238000010926 purge Methods 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 229910052720 vanadium Inorganic materials 0.000 claims description 10
- 108700040132 Mevalonate kinases Proteins 0.000 claims description 9
- 102100024279 Phosphomevalonate kinase Human genes 0.000 claims description 9
- 102000004357 Transferases Human genes 0.000 claims description 9
- 108090000992 Transferases Proteins 0.000 claims description 9
- 102000002678 mevalonate kinase Human genes 0.000 claims description 9
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 9
- 108091000116 phosphomevalonate kinase Proteins 0.000 claims description 9
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- UIAFKZKHHVMJGS-UHFFFAOYSA-N 2,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1O UIAFKZKHHVMJGS-UHFFFAOYSA-N 0.000 claims description 8
- 108010007843 NADH oxidase Proteins 0.000 claims description 8
- RNBGYGVWRKECFJ-ARQDHWQXSA-N beta-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ARQDHWQXSA-N 0.000 claims description 8
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 claims description 8
- 108010006229 Acetyl-CoA C-acetyltransferase Proteins 0.000 claims description 7
- 102000005345 Acetyl-CoA C-acetyltransferase Human genes 0.000 claims description 7
- 108010075293 Cannabidiolic acid synthase Proteins 0.000 claims description 7
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 7
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 7
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 claims description 7
- 108060000514 aromatic prenyltransferase Proteins 0.000 claims description 7
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 claims description 6
- LJQLQCAXBUHEAZ-UWTATZPHSA-N 3-phospho-D-glyceroyl dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@@H](O)C(=O)OP(O)(O)=O LJQLQCAXBUHEAZ-UWTATZPHSA-N 0.000 claims description 6
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 claims description 6
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims description 6
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims description 6
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 claims description 6
- 102000001105 Phosphofructokinases Human genes 0.000 claims description 6
- 108010069341 Phosphofructokinases Proteins 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 229940016667 resveratrol Drugs 0.000 claims description 6
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 claims description 5
- 108010000775 Hydroxymethylglutaryl-CoA synthase Proteins 0.000 claims description 5
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 claims description 5
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 claims description 5
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 claims description 5
- 108700015934 Triose-phosphate isomerases Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 claims description 4
- 102100038390 Diphosphomevalonate decarboxylase Human genes 0.000 claims description 4
- 101710183613 Diphosphomevalonate decarboxylase Proteins 0.000 claims description 4
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 claims description 4
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 claims description 4
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims description 4
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 4
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 4
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- 229940114055 beta-resorcylic acid Drugs 0.000 claims description 4
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 102200002865 rs199474729 Human genes 0.000 claims description 4
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 claims description 3
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 claims description 3
- 229940117893 apigenin Drugs 0.000 claims description 3
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 claims description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 2
- 235000008714 apigenin Nutrition 0.000 claims description 2
- 101150015622 pyk gene Proteins 0.000 claims 4
- 102220480901 Uncharacterized protein EXOC3-AS1_V49S_mutation Human genes 0.000 claims 3
- 101100310802 Dictyostelium discoideum splA gene Proteins 0.000 claims 2
- 101150056978 HMGS gene Proteins 0.000 claims 2
- 101100011891 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ERG13 gene Proteins 0.000 claims 2
- 101150100525 pykA gene Proteins 0.000 claims 2
- 101150053304 pykF gene Proteins 0.000 claims 2
- YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 claims 1
- 108010002998 NADPH Oxidases Proteins 0.000 claims 1
- 102000004722 NADPH Oxidases Human genes 0.000 claims 1
- 102220351514 c.146T>G Human genes 0.000 claims 1
- 230000009483 enzymatic pathway Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 19
- 210000004671 cell-free system Anatomy 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 description 99
- 102000004169 proteins and genes Human genes 0.000 description 55
- 235000018102 proteins Nutrition 0.000 description 50
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 42
- 230000014509 gene expression Effects 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 32
- 239000000047 product Substances 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 239000002207 metabolite Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 19
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 108700023175 Phosphate acetyltransferases Proteins 0.000 description 17
- 108020004705 Codon Proteins 0.000 description 16
- 239000007983 Tris buffer Substances 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 101100166240 Cannabis sativa CBDAS gene Proteins 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 102000053602 DNA Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 102100039824 Pre T-cell antigen receptor alpha Human genes 0.000 description 12
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 11
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 229910019142 PO4 Inorganic materials 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 239000010452 phosphate Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- CZXWOKHVLNYAHI-LSDHHAIUSA-N 2,4-dihydroxy-3-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-propylbenzoic acid Chemical compound OC1=C(C(O)=O)C(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 CZXWOKHVLNYAHI-LSDHHAIUSA-N 0.000 description 9
- -1 CBDA and THCA Natural products 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 229930014544 aromatic polyketide Natural products 0.000 description 9
- 125000003822 aromatic polyketide group Chemical group 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229930014626 natural product Natural products 0.000 description 9
- 102100032534 Adenosine kinase Human genes 0.000 description 8
- 108020000543 Adenylate kinase Proteins 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 230000037353 metabolic pathway Effects 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 101001120927 Cannabis sativa 3,5,7-trioxododecanoyl-CoA synthase Proteins 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- CRUILBNAQILVHZ-UHFFFAOYSA-N 1,2,3-trimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1OC CRUILBNAQILVHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- IRMPFYJSHJGOPE-UHFFFAOYSA-N olivetol Chemical compound CCCCCC1=CC(O)=CC(O)=C1 IRMPFYJSHJGOPE-UHFFFAOYSA-N 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 5
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000034659 glycolysis Effects 0.000 description 5
- 108060004127 isopentenyl phosphate kinase Proteins 0.000 description 5
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 229930001119 polyketide Natural products 0.000 description 5
- 150000003881 polyketide derivatives Chemical class 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000003505 terpenes Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 241000385741 Rickettsia bellii RML369-C Species 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 238000007824 enzymatic assay Methods 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000012269 metabolic engineering Methods 0.000 description 4
- 229940117954 naringenin Drugs 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 4
- 239000011678 thiamine pyrophosphate Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 3
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical group OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- NUHSROFQTUXZQQ-UHFFFAOYSA-N Isopentenyl diphosphate Natural products CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 108030006655 Olivetolic acid cyclases Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229940045189 glucose-6-phosphate Drugs 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- OEXFMSFODMQEPE-HDRQGHTBSA-N hexanoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OEXFMSFODMQEPE-HDRQGHTBSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- CPJRRXSHAYUTGL-UHFFFAOYSA-N isopentenyl alcohol Chemical compound CC(=C)CCO CPJRRXSHAYUTGL-UHFFFAOYSA-N 0.000 description 3
- IPFXNYPSBSIFOB-UHFFFAOYSA-N isopentyl pyrophosphate Chemical compound CC(C)CCO[P@](O)(=O)OP(O)(O)=O IPFXNYPSBSIFOB-UHFFFAOYSA-N 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229930015704 phenylpropanoid Natural products 0.000 description 3
- 125000001474 phenylpropanoid group Chemical group 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229940030010 trimethoxybenzene Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- SIGQQUBJQXSAMW-ZCFIWIBFSA-N (R)-5-diphosphomevalonic acid Chemical compound OC(=O)C[C@@](O)(C)CCOP(O)(=O)OP(O)(O)=O SIGQQUBJQXSAMW-ZCFIWIBFSA-N 0.000 description 2
- OKZYCXHTTZZYSK-ZCFIWIBFSA-N (R)-5-phosphomevalonic acid Chemical compound OC(=O)C[C@@](O)(C)CCOP(O)(O)=O OKZYCXHTTZZYSK-ZCFIWIBFSA-N 0.000 description 2
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- GXIURPTVHJPJLF-UWTATZPHSA-N 2-phosphoglycerate Natural products OC[C@H](C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UWTATZPHSA-N 0.000 description 2
- GXIURPTVHJPJLF-UHFFFAOYSA-N 2-phosphoglyceric acid Chemical compound OCC(C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241001465318 Aspergillus terreus Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000276440 Borrelia burgdorferi B31 Species 0.000 description 2
- 241000127145 Buchnera aphidicola BCc Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 2
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- GDFAOVXKHJXLEI-UHFFFAOYSA-N L-N-Boc-N-methylalanine Natural products CNC(C)C(O)=O GDFAOVXKHJXLEI-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000135402 Synechococcus elongatus PCC 6301 Species 0.000 description 2
- 241000999852 Treponema pallidum subsp. pallidum str. Nichols Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108020002494 acetyltransferase Proteins 0.000 description 2
- 102000005421 acetyltransferase Human genes 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 238000012938 design process Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000007905 drug manufacturing Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 150000002402 hexoses Chemical class 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 2
- 229960002950 novobiocin Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 108060006174 phosphomevalonate decarboxylase Proteins 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229930008679 prenylflavonoid Natural products 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- IQSYWEWTWDEVNO-ZIAGYGMSSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCC)C(C(O)=O)=C1O IQSYWEWTWDEVNO-ZIAGYGMSSA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- GHURLXDGHMZIGJ-UHFFFAOYSA-N 4-hydroxy-6-(2-oxoheptyl)pyran-2-one Chemical compound CCCCCC(=O)CC1=CC(O)=CC(=O)O1 GHURLXDGHMZIGJ-UHFFFAOYSA-N 0.000 description 1
- YIXLDRQOKWESBI-UHFFFAOYSA-N 4-hydroxy-6-pentylpyran-2-one Chemical compound CCCCCC1=CC(O)=CC(=O)O1 YIXLDRQOKWESBI-UHFFFAOYSA-N 0.000 description 1
- 101710134681 40 kDa protein Proteins 0.000 description 1
- OIVPAQDCMDYIIL-UHFFFAOYSA-N 5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-7-propylchromene-6-carboxylic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCC)C(C(O)=O)=C2O OIVPAQDCMDYIIL-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010092060 Acetate kinase Proteins 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 241000193798 Aerococcus Species 0.000 description 1
- 241000193792 Aerococcus viridans Species 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101100503323 Artemisia annua FPS1 gene Proteins 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000952414 Bacillus subtilis BEST7613 Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 101150009300 CBDAS gene Proteins 0.000 description 1
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 101100005358 Cannabis sativa CBCAS gene Proteins 0.000 description 1
- 101100260296 Cannabis sativa THCAS gene Proteins 0.000 description 1
- 101000712615 Cannabis sativa Tetrahydrocannabinolic acid synthase Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000191368 Chlorobi Species 0.000 description 1
- 241001142109 Chloroflexi Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000252867 Cupriavidus metallidurans Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000246067 Deinococcales Species 0.000 description 1
- MTVOSXTZNVKGIF-UHFFFAOYSA-N Dihydronitidine Natural products C1=C2C(N(C)CC=3C=C(C(=CC=33)OC)OC)=C3C=CC2=CC2=C1OCO2 MTVOSXTZNVKGIF-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 description 1
- 241000230562 Flavobacteriia Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108010026318 Geranyltranstransferase Proteins 0.000 description 1
- 101100503326 Gibberella fujikuroi FPPS gene Proteins 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241001235200 Haemophilus influenzae Rd KW20 Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102220470881 Interferon-induced protein with tetratricopeptide repeats 1_D34A_mutation Human genes 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000534259 Listeria welshimeri serovar 6b str. SLCC5334 Species 0.000 description 1
- 102100026665 Malonate-CoA ligase ACSF3, mitochondrial Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001098757 Methylobacterium nodulans ORS 2060 Species 0.000 description 1
- 241001337206 Methylomicrobium album BG8 Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000052923 Mycobacterium avium subsp. paratuberculosis K-10 Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000765897 Mycobacterium tuberculosis C Species 0.000 description 1
- 241000902584 Mycobacterium tuberculosis str. Haarlem Species 0.000 description 1
- 241000863420 Myxococcus Species 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710199606 Oxalate-CoA ligase Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000432806 Pasteurella multocida subsp. multocida str. Pm70 Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000589952 Planctomyces Species 0.000 description 1
- 108010030975 Polyketide Synthases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 102000019337 Prenyltransferases Human genes 0.000 description 1
- 108050006837 Prenyltransferases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241001209206 Pseudomonas fluorescens Pf0-1 Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 241000190984 Rhodospirillum rubrum Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241001287863 Rickettsia felis URRWXCal2 Species 0.000 description 1
- 241000109402 Rosa palustris Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000617452 Salmonella enterica subsp. enterica serovar Typhi str. AG3 Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001454746 Streptomyces niveus Species 0.000 description 1
- IQSYWEWTWDEVNO-UHFFFAOYSA-N THCVA Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCC)C(C(O)=O)=C2O IQSYWEWTWDEVNO-UHFFFAOYSA-N 0.000 description 1
- 241000204315 Thermosipho <sea snail> Species 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000020598 Vibrio nigripulchritudo ATCC 27043 Species 0.000 description 1
- 241001509381 Wigglesworthia glossinidia endosymbiont of Glossina brevipalpis Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical group OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 108010060641 flavanone synthetase Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- SKOWZLGOFVSKLB-UHFFFAOYSA-N hypodiboric acid Chemical compound OB(O)B(O)O SKOWZLGOFVSKLB-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 108010089734 malonyl-CoA synthetase Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- NXPPAOGUKPJVDI-UHFFFAOYSA-N naphthalene-1,2-diol Chemical class C1=CC=CC2=C(O)C(O)=CC=C21 NXPPAOGUKPJVDI-UHFFFAOYSA-N 0.000 description 1
- FZZQNEVOYIYFPF-UHFFFAOYSA-N naphthalene-1,6-diol Chemical compound OC1=CC=CC2=CC(O)=CC=C21 FZZQNEVOYIYFPF-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 101150057733 novQ gene Proteins 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- KXFJZKUFXHWWAJ-UHFFFAOYSA-N p-hydroxybenzoylformic acid Natural products OC(=O)C(=O)C1=CC=C(O)C=C1 KXFJZKUFXHWWAJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000007951 prenylflavonoids Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220005464 rs35203445 Human genes 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
- C12Y102/03003—Pyruvate oxidase (1.2.3.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01008—Phosphate acetyltransferase (2.3.1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01039—4-Hydroxybenzoate polyprenyltransferase (2.5.1.39)
Definitions
- Prenylation of natural compounds adds structural diversity, alters biological activity, and enhances therapeutic potential. Prenylated compounds often have low natural abundance or are difficult to isolate. Some prenylated natural products include a large class of bioactive molecules with demonstrated medicinal properties. Examples include prenyl-flavanoids , prenyl- stilbenoids, and cannabinoids
- Cannabinoids are a large class of bioactive plant derived natural products that regulate the cannabinoid receptors (CB1 and CB2) of the human endocannabinoid system. Cannabinoids are promising pharmacological agents with over 100 ongoing clinical trials investigating their therapeutic benefits as antiemetics, anticonvulsants, analgesics and antidepressants. Further, three cannabinoid therapies have been FDA approved to treat chemotherapy induced nausea, MS spasticity and seizures associated with severe epilepsy .
- cannabinoids Despite their therapeutic potential, the production of pharmaceutical grade (>99%) cannabinoids still face major technical challenges. Cannibis plants like marijuana and hemp produce high levels of tetrahydrocannabinolic (THCA) and cannibidiolic acid (CBDA) , along with a variety of lower abundance cannabinoids.
- THCA tetrahydrocannabinolic
- CBDA cannibidiolic acid
- the disclosure provides a recombinant polypeptide comprising a sequence selected from the group consisting of: (a)
- SEQ ID NO: 30 and having at least a Y288X mutation, wherein X is A, N, S, V or a non-natural amino acid; (b) SEQ ID NO: 30 having at least a Y288X mutation, wherein X is A, N, S, V or a non-natural amino acid and at least one other mutation selected from V49Zi, F213Z 2 , A232S, I234T, V271Z 3 and/or G286S, wherein Zi S, N, T or G,
- Z 2 is H, N or G and Z 3 is N or H; (c) any of the mutations
- any of (a), (b) or (c) comprising from 1-20 conservative amino acid substitutions and having NphB prenyltrans ferase activity; (e) a sequence that is at least 85%, 90%, 95%, 98% or 99% identical to SEQ ID NO: 30 and which has at least the mutations recited in (a) , (b) or (c) ; (f) a sequence recited in SEQ ID Nos: 1-28 or 29 beginning at amino acid 21; and (g) any sequence that is at least 99% identical to any of SEQ ID Nos: 1-28 or 29, wherein the polypeptide of any of (a) - (g) perform prenylation reactions.
- the prenylation reaction comprises the production of CBGA from GPP and Olivetolate or CBGVA from GPP and divarinic acid or CBGXA from a 2,4-dihydroxy benzoic acid or derivative thereof with a chemical group at the C6 position (see, e.g., Formula I) .
- 'X' can be a halo, hydroxyl, cyano, nitro, ester, alkoxy, amino, thiol, sulfinyl, sulfonyl, sulfino, sulfo, thiocyanato, isothiocyanato, thial, borono, boronate, phosphate, aldehyde, carboxyl, carboxamido, azido, cyanato, isocyanato, an optionally substituted (Ci-Cio) alkyl, an optionally substituted (C2-C10) alkenyl, an optionally substituted (C2-C10) alkynyl, an optionally substituted (C1-C10) hetero-alkyl, an optionally substituted (C2-C10) hetero alkenyl, an optionally substituted (C2-C10) hetero-alkynyl, an optionally substituted (C3-C10) cycloalkyl, an optionally substituted ary
- X is a substituted or unsubstituted alkyl containing 2 to 10 carbons.
- the disclosure also provides a recombinant pathway comprising a polypeptide having a sequence a sequence selected from the group consisting of: (a) SEQ ID NO: 30 and having at least a Y288X mutation, wherein X is A, N, S, V or a non-natural amino acid; (b) SEQ ID NO: 30 having at least a Y288X mutation, wherein X is A, N, S, V, or a non-natural amino acid and at least one other mutation selected from V49Zi, F213Z 2 , A232S, I234T, V271Z 3 and/or G286S, wherein Zi S, N, T or G, Z 2 is H, N or G and Z 3 is N or H;
- the method further comprises a pyruvate dehydrogenase bypass enzymatic pathway comprising a pyruvate oxidase and an acetyl phosphate transferase.
- the pathway comprises a "purge valve" that recycles NADH/NAD and NADPH/NADP.
- the pathway comprises the following enzymes: (i) hexokinase (Hex) ; (ii) Glucose- 6-phosphate isomerase (Pgi) ; (iii) Phosphofructokinase (Pfk) ; (iv) Fructose-1 , 6-bisphosphate aldolase (Fba) ; (v) Triose phosphate isomerase (Tpi) ; (vi) Gald-3-P dehydrogenase (Gap) ; (vii) a mutant Gald-3-P dehydrogenase (mGap) ; (viii) NADH Oxidase (Nox) ; (ix) Phosphoglycerate Kinase (Pgk) ; (x)
- Phosphoglycerate Mutase (2,3 BPG dependent) (dPgm) ; (xi) Enolase (eno) ; (xii) Pyruvate Kinase (FBP dependent) ; (xiii) Pyruvate Oxidase (PyOx) ; (xiv) Acetyl-phosphate transferase (PTA) ; (xv) Acetyl-CoA acetyltrans ferase (PhaA) ; (xvi) HMG-CoA Synthase (HMGS) ; (xvii) HMG-CoA Reductase (HMGR) ; (xviii) Mevalonate Kinase (MVK) ; (xix) Phosphomevalonate Kinase (PMVK) ; (xx) Diphosphomevalonate decarboxylase (MDC) ; (xxi) isopentenyl diphosphate isomerase (IDI); (xx
- the pathway comprises a 4-step pathway to convert isoprenol or prenol to GPP using ATP and one or more steps to recycle ADP/ATP.
- the pathway omprises (a) (iso)prenol kinase (PRK) ; (b) isopentenyl phosphate kinase
- IPK isopentenyl diphosphate isomerase
- IDI isopentenyl diphosphate isomerase
- GPPS geranyl pyrophosphate synthase
- the pathway is supplemented with ATP and olivetolate (or 2,4-dihydroxy benzoic acid or derivative thereof) and the pathway produces a cannabinoid precursor.
- the pathway further comprises a cannabidiolic acid synthase.
- the pathway produces
- the disclosure also provides a method of producing a prenylated compound comprising contacting a substrate with a prenyl-group having the general structure:
- FIG. 1A-B depicts exemplary biosynthetic pathways of the disclosure.
- A The synthetic biochemistry platform for the production of prenylnatural products. First, glucose is broken down into pyruvate through a glycolysis pathway modified to regulate NADPH levels (12 enzymatic steps) . Then, either PDH or the PDH bypass converts pyruvate into acetyl-CoA. Acetyl-CoA is converted into GPP via the mevalonate pathway (eight enzymatic steps) .
- aromatic prenyltrans ferase (aPT) and aromatic substrate various prenyl-flavonoids and prenyl-stilbenoids using the same central pathway can be produced.
- CBGA is converted to cannabidiolic acid (CBDA) and CBGVA is converted to cannabidivaric acid (CBDVA) via cannabidiolic acid synthase
- (CBDAS) cannabinoid synthases
- THCAS and CBCAS cannabinoid synthases
- B Depicts a more detailed view of the pathway of (A) . Glucose is broken down into pyruvate through glycolysis (dark blue) . The purge valve outlined in dark blue allows carbon flux to continue through the glycolysis pathway without building up excess NADPH. Pyruvate is converted to acetyl-CoA through the PDH bypass outlined in light blue. Acetyl-CoA is built up into high energy phosphate molecules through the mevalonate pathway (aqua) to produce GPP.
- Figure 3A-C shows the engineering of NphB to improve
- Figure 4A-C shows the evaluation of the cell-free prenylation system for the production of various cannabinoids .
- CBGA production using M23 is shown in the light green trace and WT NphB in the dark green trace.
- the production of CBGVA using M31 is shown in the light blue trace.
- B Using a nonane flow CBGA capture system, a higher titer of CBGA (1.2 g/L) was obtained.
- the nonane layer was exchanged using a peristaltic pump, which circulated the nonane in the direction indicated by the arrows.
- CBDA production is shown in the dark purple trace
- CBDVA production is shown in the light purple trace.
- Figure 5A-C shows Pathway schematics for the MatB
- MdcA (transferase) paths This is the schematic for the MatB path. The malonyl-CoA production is ATP dependent, but otherwise not connected with the pathway. A titer is the the pathway is 12 mg/L.
- B This is the schematic for the MdcA transferase path. The malonyl-CoA production is no longer ATP dependent, and is tied in to the pyruvate oxidation path, and the mevalonate path. A titer for the system is 42 mg/L.
- C shows additional detail of exemplary steps in the polyketide module of the pathway shows in (A) and (B) .
- Figure 6 shows a pathway schematic for the (iso)prenol to GPP paths. Isoprenol or prenol can be turned in to
- Figure 7 shows the various canonical (Eukaryotic) and non-canonical (Archael I and II) mevalonate pathways that can be used to generate IPP/DMAPP from acetyl-CoA (or mevalonate) .
- Prenylation also known as isoprenylation or lipidation
- isoprenylation or lipidation is the addition of hydrophobic molecules to a protein or chemical compound. It is usually assumed that prenyl groups (3-methylbut-2- en-l-yl) facilitate attachment to cell membranes, similar to lipid anchors like the GPI anchor. Prenyl groups have been shown to be important for protein-protein binding through specialized prenyl binding domains .
- Prenylated natural products are a large class of bioactive molecules with demonstrated medicinal properties.
- prenyl-flavanoids examples include prenyl-flavanoids , prenyl-stilbenoids , and cannabinoids .
- Plant-derived prenylcompounds are difficult to isolate due to the structural similarity of contaminating
- Microbial production is a useful alternative to natural extraction for prenylated natural products, but comes with many challenges such as the need to divert carbon flux from central metabolism and product toxicity to name a few.
- prenyl- natural products like prenyl-naringenin, prenyl-resveratrol , and cannabidiolic acid (CBDA) are derived from a combination of the metabolic pathways for fatty acid, isoprenoid, and polyketide biosynthesis. So, high-level production requires efficient rerouting of long, essential and highly regulated pathways.
- GPP geranyl-pyrophosphate
- Cannabinoids in particular show immense therapeutic potential with over 100 ongoing clinical trials as antiemetics, anticonvulsants, antidepressants, and analgesics. Nevertheless, despite the therapeutic potential of prenyl-natural products, their study and use is limited by the lack of cost-effective production methods .
- THCA cannabinoids
- cannibichromene or CBCA are derived from a single precursor, CBGA. Additionally, three low abundance cannabinoids are derived from CBGVA (Fig . 1A) . Thus, the ability to make CBGA and CBGVA in a heterologous host would open the door to the production of an array of cannabinoids. Unfortunately, engineering microorganisms to produce CBGA and CBGVA has proven extremely challenging.
- Cannabinoids are derived from a combination of fatty acid, polyketide, and terpene biosynthetic pathways that generate the key building blocks geranyl pyrophosphate (GPP) and olivetolic acid (OA) (Fig. 1A) .
- Synthetic biochemistry in which complex biochemical conversions are performed cell-free using a mixture of enzymes, affords potential advantages over traditional metabolic engineering including: a higher level of flexibility in pathway design; greater control over component optimization; more rapid design-build-test cycles; and freedom from cell toxicity of intermediates or products.
- the disclosure provides a cell-free system for the production of cannabinoids.
- This disclosure provides enzyme variants and pathways comprising such variants for the prenylation of compounds including the production of cannabinoids.
- biosynthetic pathways described herein use “purge valves” to regulate NAD(P)H levels. Such "purge valves” have demonstrated high level
- WO2017/015429 the disclosure of which is incorporated herein by reference.
- These purge valves were used to upgrade and diversify the original system to produce complex natural products like cannabinoids.
- a synthetic biochemistry approach is outlined in Fig. 1A, IB, 5A and 5B.
- the disclosure provides a cell-free system for prenylation using GPP derived from glucose (see, Fig. 1A, IB, 5A, 5B and 7) .
- the disclosure provides a cell-free system for prenylation using GPP derived from (iso)prenol or prenol (see, Fig. 6) .
- Fig. 6 can be coupled to any ATP generating system to produce the ATP needed for a reaction.
- the pathway can be coupled with a creatine kinase ATP generating system; an acetate kinase system; a glycolysis system as well as others.
- Enzymes (nucleic acid coding sequences and polypeptides) of Fig. 6 are provided in SEQ ID NOs : 54-65 (e.g., PRK enzymes are provided in SEQ ID NOs :
- IPK enzymes are provided in SEQ ID NOs: 58-61; IDI enzymes are provided in SEQ ID NOs: 62-63; and FPPS enzymes are provided in SEQ ID NOs : 64-65) .
- NphB is an aromatic prenyltransferase that catalyzes the attachment of a 10-carbon geranyl group to aromatic substrates.
- NphB exhibits a rich substrate selectivity and product
- NphB identified from Streptomyces, catalyzes the addition of a 10-carbon geranyl group to a number of small organic aromatic substrates.
- NphB has a spacious and solvent accessible binding pocket in to which two substrates molecules, geranyl diphosphate (GPP) and 1 , 6-dihydroxynaphthalene (1,6-DHN), can be bound.
- GPP is stabilized via interactions between its negatively charged diphosphate moiety and several amino acid sidechains, including Lysll9, Thrl71, Arg228, Tyr216 and Lys284, in addition to Mg 2+ .
- a Mg 2+ cofactor is required for the activity of NphB.
- NphB from Streptomyces has a sequence as set forth in SEQ ID NO: 30.
- NovQ (accession no. AAF67510, incorporated herein by reference) is a member of the CloQ/NphB class of
- the novQ gene can be cloned from Streptomyces niveus, which produces an aminocoumarin antibiotic, novobiocin.
- Recombinant NovQ can be expressed in Escherichia coli and purified to homogeneity.
- the purified enzyme is a soluble monomeric 40-kDa protein that catalyzed the transfer of a dimethylallyl group to 4- hydroxyphenylpyruvate (4-HPP) independently of divalent cations to yield 3-dimethylallyl-4-HPP, an intermediate of novobiocin.
- NovQ catalyzed carbon-carbon- based and carbon-oxygen-based prenylations of a diverse collection of phenylpropanoids , flavonoids and dihydroxynaphthalenes . Despite its catalytic promiscuity, the NovQ-catalyzed prenylation occurred in a regiospecific manner. NovQ is the first reported
- prenyltrans ferase capable of catalyzing the transfer of a
- AtaPT Aspergillus terreus aromatic prenyltrans ferase
- AtaPT accession no. AMB20850, incorporated herein by reference
- AtaPT Recombinant AtaPT can be overexpressed in Escherichia coli and purified.
- Aspergillus terreus aromatic prenyltrans ferase (AtaPT) catalyzes predominantly C-monoprenylation of acylphloroglucinols in the presence of different prenyl diphosphates.
- Olivetolic acid (OA) is a relatively poor substrate for wild-type NphB.
- 1,6 dihydroxynapthalene (1,6 DHN) 1,6 dihydroxynapthalene
- About 400 mg/L (1.3 mM) of prenylated product was obtained when starting with 2.5 mM 1,6 DHN and 500 mM glucose.
- 1,6 DHN concentration was increased from 2.5 to 5 mM, final titers decreased 2-fold suggesting that 1,6 DHN was inhibiting one or more enzymes.
- Enzyme assays revealed that E. coli pyruvate
- Fig. 2A the new system removed the inhibition seen at higher concentrations of 1, 6 DHN and increased titers of 5-prenyl-l,6 DHN 4-fold over the PDH system when starting at 5 mM 1,6 DHN (Fig. 2B) .
- Fig. 2C shows a time course of 5-prenyl- 1,6 DHN biosynthesis starting with 5 mM 1,6 DHN utilizing the PDH bypass. Approximately 50% of the 1,6 DHN was converted in the first 24 hours, ultimately reaching a final titer of 705 ⁇ 12 mg/L.
- NphB The prenylation of aromatic polyketides by NphB is thought to proceed through a carbocation intermediate in which the first step is dissociation of diphosphate from GPP to create a carbocation on the Cl carbon of GPP, which subsequently attacks a nearby nucleophile.
- OA was modeled into the active site of NphB using the crystal structure of NphB in complex with 1,6 DHN, Mg 2+ and a nonhydrolyzable analog of GPP (geranyl S-thiolodiphosphate ) as a starting point (PDBID 1ZB6; Protein Data Bank reference 1ZB6) .
- OA was placed into the binding pocket using 1,6 DHN as a guide, situating the desired prenylation site, the C3 carbon of OA, 3.7 A above the nascent geranyl Cl carbocation (Fig. 3A) .
- the distance chosen was based on the distance of the C5 carbon of 1,6 DHN to the Cl carbon of GPP. Residues in contact with OA were then varied using ROSETTA software to optimize the active site of NphB for binding OA. Side chains in contact with GPP or that
- Table 1 provides exemplary mutations and the fold improvement relative to wild type (i.e., a polypeptide of SEQ ID NO: 30) .
- NphB library constructs and mutations (amino acid positions referenced to SEQ ID NO: 30) .
- NphB M1 0.061 ⁇ 0.003 0.58 ⁇ 0.1 1 0.1 1 ⁇ 0.02
- NphB M30 1.07 ⁇ 0.05 0.25 ⁇ 0.05 4.2 ⁇ 0.9
- NphB M31 1.30 ⁇ 0.05 0.12 ⁇ 0.02* 10.8 ⁇ 2.1
- NphB polypeptides of the disclosure are described herein.
- the polypeptides may be produced by direct peptide synthesis using solid-phase techniques (e.g., Stewart et al. (1969) Solid-Phase Peptide Synthesis (WH Freeman Co, San Francisco) ; and Merrifield (1963) J. Am. Chem. Soc. 85: 2149-2154; each of which is incorporated by reference) .
- Peptide synthesis may be performed using manual techniques or by
- Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City, Calif.) in accordance with the instructions provided by the manufacturer .
- F213N had a neutral or deleterious effect in the Y288A/F213N (M5) construct suggesting that A232S may also be a favorable mutation.
- the designed mutant M23 not only shows dramatically improved catalytic efficiency for prenylation of OA, it is also extremely specific, producing only the correct CBGA product. WT NphB produces CBGA, but the dominant product is a prenylated isomer (FIG. 3C) . In contrast the designed mutant M23 makes CBGA almost exclusively. Overall, the designed enzyme is a much more effective CBGA synthase than the non-specific prenylating wild-type enzyme.
- mutant NphB variants comprising (i) SEQ ID NO: 30 and having at least a Y288X mutation, wherein X is A, N, S, V or a non-natural amino acid; (ii) SEQ ID NO: 30 having at least a Y288X mutation, wherein X is A, N, S, V or a non-natural amino acid, and at least one other mutation selected from V49Zi, F213Z 2 , A232S, I234T, V271Z 3 and/or G286S, wherein Zi S, N, T or G, Z 2 is H, N or G and Z 3 is N or H; (iii) any of the mutations combination set forth in Table 1; (iv) any of (i) , (ii) or (iii) comprising from 1-20 (e.g., 2, 5, 10, 15 or 20; or any value between 1 and 20) conservative amino acid substitutions and having NphB activity; (v) a
- a non-natural amino acid refers to amino acids that do not occur in nature such as N-methyl amino acids (e.g., N-methyl L-alanine, N-methyl L-valine etc.) or alpha-methyl amino acids, beta-homo amino acids, homo- amino acids and D-amino acids.
- a non-natural amino acid useful in the disclosure includes a small hydrophobic non-natural amino acid (e.g., N-methyl L-alanine, N-methyl L-valine etc.) .
- the disclosure provides polynucleotides encoding any of the foregoing NphB variants. Due to the
- the disclosure also provide recombinant host cells and cell free systems comprising any of the NphB variant enzymes of the disclosure.
- the recombinant cells and cell free systems are used carry out prenylation processes.
- One objective of the disclosure is to produce the precursor GPP from glucose or prenol and/or isoprenol, which can then be used to prenylate added OA with a mutant NphB of the disclosure, thereby generating CBGA.
- the disclosure thus provides a cell-free system comprising a plurality of enzymatic steps that converts glucose to geranyl pyrophosphate, wherein the pathway includes a purge valve and a PDH bypass enzymatic process.
- one pathway of the disclosure comprises converting glucose to glucose- 6-phosphate using a hexokinase.
- a hexokinase (EC 2.7.1.1) is an enzyme that
- Hexokinase phosphorylates hexoses (six-carbon sugars), forming hexose phosphate.
- Hexokinase possesses the ability to transfer an inorganic phosphate group from ATP to a substrate. Numerous hexokinase proteins from various organisms have been cloned and expressed.
- the hexokinase comprises the sequence set forth in UniProtKB accession number P04806 from
- Saccharomyces cerevisiae (incorporated herein by reference) as well as sequences that are at least 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% identical thereto and have hexokinase activity.
- phosphoglucoisomerase or "Pgi” refer to proteins that are capable of catalyzing the formation of fructose- 6-phosphate from glucose-6- phosphate, and which share at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or greater sequence identity to SEQ ID NO: 31, or at least about 50%, 60%, 70%,
- recombinant microorganism includes expression of a phosphofructokinase (Pfk, polyphosphate-dependent Pfk or homolog or variants thereof) .
- Pfk phosphofructokinase
- This expression may be combined with other enzymes in the metabolic pathway.
- the Pfk can be derived from G. stearothermophilus (SEQ ID NO: 32) .
- an engineered variant of Pfk can be used so long as it has
- phosphofructokinase activity and can convert fructose- 6-phosphate to fructose-1, 6-bisphosphate .
- Such engineered variants can be obtained by site-directed mutagenesis, directed evolutions and the like.
- polypeptides that are at least 85-99% identical to a sequence as set forth in SEQ ID NO: 32 and having phosphofructokinase activity (see, e.g., SEQ ID NOs : 33-34) .
- fructose 1,6 bisphosphate aldolase or "Fba” refer to proteins that are capable of catalyzing the formation of dihydroxyacetone phosphate and glyceraldehyde-3-phosphate from fructose 1 , 6-bisphosphate , and which share at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or greater sequence identity, or at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or greater sequence similarity, as calculated by NCBI BLAST, using default parameters, to SEQ ID NO: 35.
- Additional homologs include: Synechococcus elongatus PCC 6301 YP_170823.1 having 26% identity to SEQ ID NO: 35; Vibrio nigripulchritudo ATCC 27043 ZP_08732298.1 having 80% identity to SEQ ID NO:35;
- Methylomicrobium album BG8 ZP_09865128.1 having 76% identity to SEQ ID NO: 35; Pseudomonas fluorescens Pf0-1 YP_350990.1 having 25% identity to SEQ ID NO: 35; and Methylobacterium nodulans ORS 2060 YP_002502325.1 having 24% identity to SEQ ID NO: 35.
- the disclosure includes the use of polypeptides having from 26% to 100% identity to SEQ ID NO: 35, wherein the polypeptide has bisophosphate aldolase activity.
- the terms “triose phosphate isomerase” or “Tpi” refer to proteins that are capable of catalyzing the formation of glyceraldehyde-3-phosphate from dihydroxyacetone phosphate (DHAP) , and which share at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or greater sequence identity, or at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or greater sequence similarity, as calculated by NCBI BLAST, using default parameters, to SEQ ID NO: 36. Additional homologs include: Rattus norvegicus AAA42278.1 having 45% identity to SEQ ID NO: 36; Homo sapiens
- AAH17917.1 having 45% identity to SEQ ID NO: 36
- Bacillus subtilis BEST7613 NP_391272.1 having 40% identity to SEQ ID NO: 36;
- the disclosure incudes the use of polypeptides that have from 40% to 100% identity to SEQ ID NO: 36 and have triose phosphate isomerase activity.
- the sequences associated with the foregoing accession numbers are incorporated herein by reference.
- glyceraldehyde-3- phosphate can be converted to 1 , 3-bisphosphoglycerate .
- This enzymatic step can include a "purge valve system" (as discussed elsewhere herein) .
- glyceraldehyde-3-phosphate dehydrogenase (Gap, Tdh) converts glyceraldehyde-3-phosphate to 1 , 3-bisphospho-glycerate .
- a wild-type Gap is used that uses NAD + as a cofactor (see, e.g., SEQ ID NO: 37) or a mutant Gap comprising a P191D mutation (relative to the sequence of SEQ ID NO: 37 and as shown in SEQ ID NO: 38) .
- a mutant Gap (mGap; e.g., having a D34A/L35R/T35K mutation;
- a molecular purge valve comprising a water generating NADH oxidase (NoxE) that specifically oxidizes NADH, but not NADPH can be used to recycle (“purge") NADH when a wild-type gap or P118D mutant gap is used that preferentially uses NAD + .
- NoxE NADH oxidase
- NADH oxidase or “NoxE” refer to proteins that are capable of oxidizing NADH to NAD + , and which share at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or greater sequence identity, or at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or greater sequence similarity, as calculated by
- NCBI BLAST using default parameters, to SEQ ID NO: 18.
- the pathway can further convert 1 , 3-bisphosphoglycerate to 3-phosphoglycerate by use of phosphoglycerate kinase (EC
- PGK e.g., as provided in SEQ ID NO:40, or a homolog or variant thereof that is at least 80% identical thereto
- a molecular purge valve for ATP can be present to recycle ADP using, for example, a GTPase or other enzyme or a homolog or variant thereof) .
- the 3-phosphoglycerate can then be converted by a phosphoglycerate mutase (pgm; e.g., as provided in SEQ ID NO: 41, or a homolog or variant thereof that is at least 80% identical thereto) to 2-phosphoglycerate .
- a phosphoglycerate mutase pgm; e.g., as provided in SEQ ID NO: 41, or a homolog or variant thereof that is at least 80% identical thereto
- An enolase (eno; e.g., as provided in SEQ ID NO: 42, or a homolog or variant thereof that is at least 80% identical thereto) can then convert the 2-phosphoglycerate to phosphenolpyruvate (PEP) .
- PEP phosphenolpyruvate
- a pyruvate kinase (pyk; e.g., as provided in SEQ ID NO: 1]
- pyruvate dehydrogenase is inhibited by products of the pathway.
- a PDH Bypass can be used to covert pyruvate to acetyl-coA.
- the PDH Bypass comprises two enzymatic steps: (i) pyruvate - ⁇ acetyl phosphate catalyzed by pyruvate oxidase (e.g., PyOx from Aerococcus viridans; EC 1.2.3.3; see SEQ ID NO: 46) ; and (ii) acetyal phosphate -> acetyl-coA catalyzed by an acetyl phosphate transferase (aka phosphate acetyltrans ferase ) (e.g., PTA from G. stearothermophilus) .
- a PyOx used in the composition and methods of the disclosure include sequences that are at least 85%, 90%, 95%, 98%, 99% identical to SEQ ID NO: 46 and have pyruvate oxidase activity.
- Phosphate acetyltrans ferase (EC 2.3.1.8) is an enzyme that catalyzes the chemical reaction of acetyl-CoA + phosphate to CoA + acetyl phosphate and vice versa.
- Phosphate acetyltrans ferase is encoded in E.coli by pta.
- PTA is involved in conversion of acetate to acetyl-CoA. Specifically, PTA catalyzes the conversion of acetyl-coA to acetyl-phosphate.
- PTA homologs and variants are known. There are approximately 1075 bacterial phosphate
- acetyltrans ferases available on NCBI .
- such homologs and variants include phosphate acetyltrans ferase Pta (Rickettsia felis URRWXCal2) gi
- acetyltrans ferase (pta) ( Treponema pallidum subsp. pallidum str. Nichols) gi
- the pathway includes the conversion of acetyl-coA to acetoacetyl-coA.
- the conversion of acetyl-coA to acetoacetyl-CoA is performed by an acetyl-CoA acetyltrans ferase (e.g., PhaA) .
- acetyl-CoA acetyltrans ferase e.g., PhaA
- Numerous acetyl-coA acetyltrans ferases are known in the art.
- acetyl-coA acetyltrans ferase from R. eutropha acetyl-coA acetyl transferase has an amino acid sequence that is at least 85%, 90%, 95%, 98%, 99% or 100% identical to SEQ ID NO:47.
- Acetoacetyl-CoA and acetyl-Coa can be converted to HMG-
- HMG-CoA synthase having an A110G mutation (see, e.g., SEQ ID NO: 48) or a homolog or variant thereof having 85%-99% sequence identity thereto.
- HMG-CoA is then reduced to mevalonate by the actions of NADPH and HMG-CoA reductase (see, e.g., SEQ ID NO: 49) or a homolog or variant thereof having from 85%-99% sequence identity thereto .
- Mevalonate is then phosphorylated by ATP and the action of mevalonate kinase (MVK) to produce mevalonate-5-phosphate and ADP.
- MVK mevalonate kinase
- Melavonate kinases are known in the art and include sequence that are at least 85-100% (e.g., 85%, 90%, 95%, 98%, 99%) identical to the sequence of SEQ ID NO: 50 and which have mevalonate kinase activity .
- the mevalonate-5-phosphate is further phosphorylated by
- Phosphomevalonate kinases include sequence that are at least 85-100% (e.g., 85%, 90%, 95%, 98%, 99%) identical to the sequence of SEQ ID NO: 51 and which have phophomevalonate kinase ativity.
- Mevalonate-5-diphosphate is decarboxylated by ATP and the actions of diphosphomevalonate decarboxylase (MDC) to produce ADP, CO2 and isopentyl pyrophosphate.
- MDC diphosphomevalonate decarboxylase
- decarboxylases are known in the art and include sequence that are at least 85-100% (e.g., 85%, 90%, 95%, 98%, 99%) identical to the sequence of SEQ ID NO: 52 and which have diphosphomevalonate kinase activity .
- Geranyl pyrophosphate is then formed from the combination of DMAPP and isopentyl pyrophosphate in the presence of farnesyl-PP synthase having an S82F mutation relative to SEQ ID NO: 53.
- the farnesyl-diphosphate synthase has a sequence that is at least 95%, 98%, 99% or 100% identical to SEQ ID NO: 53.
- GPP can then be used as a substrate for a number of pathways leading to prenyl-flavinoids, geranyl-flavonoics , prenyl- stilbenoids , geranyl-stilbenoids , CBGA, CBGVA, CBDA, CBDVA, CBGVA, CBCVA, THCA and THCVA (see, e.g., FIG.1A)
- the precipitate was collected and a mix of enzymes was identified in the precipitate by SDS-PAGE analysis, indicating that high- levels of CBGA in solution causes enzymes to precipitate. A more effective system was developed to remove product during the reaction .
- CBGVA was produced at a max productivity of ⁇ 107 mg L -1 hr -1 , and reached a final titer of 1.74 ⁇ 0.09 g L -1 , converting 92% of the divarinic acid added to CBGVA.
- the nonane flow system was not needed for the production of CBGVA because CBGVA was less potent in precipitating enzymes .
- CBDA synthase was employed to convert CBGA into CBDA and CBGVA into CBDVA.
- the nonane overlay contained a significant quantity of CBGA, so by simply transferring the nonane overlay to a solution containing CBDA synthase, CBGA was converted into CBDA at a constant rate of 14.4 ⁇ 0.8 mg L -1 hr -1 mg total protein -1 for 4 days.
- CBGVA was extracted and added to a reaction containing CBDA synthase.
- the product of the CBDA synthase was in fact CBDVA using GC-MS.
- the disclosure thus provides a cell free system for the production of GPP. Further the disclosure provides a cell free approach for the production of an array of pure cannabinoids and other prenylated natural products using the GPP pathway in
- the modularity and flexibility of the synthetic biochemistry platform provided herein has the benefits of a bio-based approach, but removes the complexities of satisfying living systems. For example, GPP toxicity did not factor into the design process.
- OA is not taken up by yeast so the approach of adding it exogenously would not necessarily be possible in cells.
- flexibility of cell free systems can greatly facilitate the design-build-test cycles required for further optimization, additional pathway enzymes and reagent and co-factor modifications.
- a step may utilize a co-factor, but some steps do not use co-factors (e.g., NAD(P)H, ATP/ADP etc.) .
- Table 3 provides a list of enzymes, organisms and reaction amounts used as well as accession numbers (the sequences associated with such accession numbers are incorporated herein by reference) .
- prenylation of olivetolate by GPP is carried out by the activity of the mutant NphB polypeptides described herein and above.
- the disclosure provides an in vitro method of producing prenylated compounds and moreover, an in vitro method for producing cannabinoids and cannabinoid precursors (e.g., CBGA, CBGVA or CBGXA where 'X' refers to any chemical group) .
- cell-free preparations can be made through, for example, three methods.
- the enzymes of the pathway, as described herein, are purchased and mixed in a suitable buffer and a suitable substrate is added and incubated under conditions suitable for production of the prenylated compound or the
- the enzyme can be bound to a support or expressed in a phage display or other surface expression system and, for example, fixed in a fluid pathway corresponding to points in the metabolic pathway's cycle.
- FIG. 5A-B depict the pathway as various "modules” (e.g., glycolysis module, mevalonate/isoprenoid module, cannabinoid module, polyketide module) .
- the isoprenoid module produces the isoprenoid geranyl pyrophosphate (GPP) from acetyl-CoA via the mevalonate pathway.
- the aromatic polyketide module utilizes a Type III polyketide synthase (PKS) to convert hexanoyl-CoA and malonyl-CoA (derived from acetyl-CoA) into olivetolic acid (OA) .
- PPS Type III polyketide synthase
- the cannabinoid module uses products from the isoprenoid module and the polyketide module to yield cannabigerolic acid, which is then converted into the final cannabinoid by a cannabinoid synthase .
- one or more polynucleotides encoding one or more enzymes of the pathway are cloned into one or more microorganism under conditions whereby the enzymes are expressed. Subsequently the cells are lysed and the lysed preparation comprising the one or more enzymes derived from the cell are combined with a suitable buffer and substrate (and one or more additional enzymes of the pathway, if necessary) to produce the prenylated compound or the cannabinoids or cannabinoid precursor. Alternatively, the enzymes can be isolated from the lysed preparations and then recombined in an appropriate buffer.
- a combination of purchased enzymes and expressed enzymes are used to provide a pathway in an appropriate buffer.
- heat stabilized polypeptide/enzymes of the pathway are cloned and expressed.
- the enzymes of the pathway are derived from thermophilic
- microorganisms The microorganisms are then lysed, the preparation heated to a temperature wherein the heat stabilized polypeptides of the pathway are active and other polypeptides (not of interest) are denatured and become inactive.
- the preparation thereby includes a subset of all enzymes in the microorganism and includes active heat-stable enzymes.
- the preparation can then be used to carry out the pathway to produce the prenylated compound or the cannabinoids or cannabinoid precursor.
- the disclosure also provides recombinant organisms comprising metabolically engineered biosynthetic pathways that comprise a mutant nphB for the production of prenylated compouds and may further include one or more additional organisms expressing enzymes for the production of cannabinoids (e.g., a co-culture of one set of microorganism expressing a partial pathway and a second set of microorganism expression yet a further or final portion of the pathway etc.) .
- cannabinoids e.g., a co-culture of one set of microorganism expressing a partial pathway and a second set of microorganism expression yet a further or final portion of the pathway etc.
- the disclosure provides a recombinant microorganism comprising elevated expression of at least one target enzyme as compared to a parental microorganism or encodes an enzyme not found in the parental organism.
- the microorganism comprises a reduction, disruption or knockout of at least one gene encoding an enzyme that competes with a metabolite necessary for the production of a desired metabolite or which produces an unwanted product.
- the microorganism expresses an enzymes that produces at least one metabolite involved in a biosynthetic pathway for the production of, for example, the prenylated compound or the cannabinoids or cannabinoid precursor.
- the recombinant microorganisms comprises at least one recombinant metabolic pathway that comprises a target enzyme and may further include a reduction in activity or expression of an enzyme in a competitive biosynthetic pathway.
- the pathway acts to modify a substrate or metabolic intermediate in the production of, for example, a prenylated compound or cannabinoids or cannabinoid precursors.
- the target enzyme is encoded by, and expressed from, a polynucleotide derived from a suitable biological source.
- the polynucleotide comprises a gene derived from a bacterial or yeast source and recombinantly engineered into the microorganism of the disclosure.
- the polynucleotide encoding the desired target enzyme is naturally occurring in the organism but is recombinantly engineered to be overexpressed compared to the naturally expression levels .
- microorganism includes prokaryotic and eukaryotic microbial species from the Domains Archaea, Bacteria and Eucarya, the latter including yeast and filamentous fungi, protozoa, algae, or higher Protista.
- microbial cells and “microbes” are used interchangeably with the term
- prokaryotes is art recognized and refers to cells which contain no nucleus or other cell organelles.
- the prokaryotes are generally classified in one of two domains, the Bacteria and the Archaea. The definitive difference between organisms of the Archaea and Bacteria domains is based on
- Bacteria refers to a domain of prokaryotic organisms. Bacteria include at least 11 distinct groups as follows: (1) Gram-positive (gram+) bacteria, of which there are two major subdivisions: (1) high G+C group (Actinomycetes ,
- Mycoplasmas Mycoplasmas ) ; (2) Proteobacteria, e.g. , Purple photosynthetic +non- photosynthetic Gram-negative bacteria (includes most "common” Gram negative bacteria); (3) Cyanobacteria, e.g., oxygenic phototrophs ; (4) Spirochetes and related species; (5) Planctomyces ; (6)
- Gram-negative bacteria include cocci, nonenteric rods, and enteric rods.
- the genera of Gram-negative bacteria include, for example, Neisseria, Spirillum, Pasteurella, Brucella, Yersinia, Francisella, Haemophilus, Bordetella, Escherichia, Salmonella, Shigella, Klebsiella, Proteus, Vibrio, Pseudomonas, Bacteroides, Acetobacter, Aerobacter, Agrobacterium, Azotobacter, Spirilla, Serratia, Vibrio, Rhizobium, Chlamydia, Rickettsia, Treponema, and Fusobacterium.
- Gram positive bacteria include cocci, nonsporulating rods, and sporulating rods.
- the genera of gram positive bacteria include, for example, Actinomyces, Bacillus, Clostridium,
- Mycobacterium Myxococcus, Nocardia, Staphylococcus, Streptococcus, and Streptomyces .
- an "activity" of an enzyme is a measure of its ability to catalyze a reaction resulting in a metabolite, i.e., to "function", and may be expressed as the rate at which the metabolite of the reaction is produced.
- enzyme activity can be represented as the amount of metabolite produced per unit of time or per unit of enzyme (e.g., concentration or weight), or in terms of affinity or dissociation constants.
- biosynthetic pathway also referred to as
- metabolic pathway refers to a set of anabolic or catabolic biochemical reactions for converting (transmuting) one chemical species into another (see, e.g., FIG. 1A-B) .
- Gene products belong to the same “metabolic pathway” if they, in parallel or in series, act on the same substrate, produce the same product, or act on or produce a metabolic intermediate (i.e., metabolite) between the same substrate and metabolite end product.
- the disclosure provides recombinant microorganism having a metabolically engineered pathway for the production of a desired product or intermediate.
- metabolically “engineered” or “modified” microorganisms are produced via the introduction of genetic material into a host or parental microorganism of choice thereby modifying or altering the cellular physiology and biochemistry of the microorganism.
- the parental microorganism acquires new properties, e.g. the ability to produce a new, or greater quantities of, an
- the introduction of genetic material into a parental microorganism results in a new or modified ability to produce acetyl-phosphate and/or acetyl-CoA through through a PDH bypass using pyruvate oxidase and
- the genetic material introduced into the parental microorganism contains gene(s), or parts of gene(s), coding for one or more of the enzymes involved in a biosynthetic pathway for the production of prenylated compounds or cannabinoids or cannabinoid precursors, and may also include additional elements for the expression and/or regulation of expression of these genes, e.g. promoter sequences.
- An engineered or modified microorganism can also include in the alternative or in addition to the introduction of a genetic material into a host or parental microorganism, the disruption, deletion or knocking out of a gene or polynucleotide to alter the cellular physiology and biochemistry of the microorganism. Through the reduction, disruption or knocking out of a gene or
- polynucleotide the microorganism acquires new or improved
- quantities of an intracellular metabolite improve the flux of a metabolite down a desired pathway, and/or reduce the production of undesirable by-products) or eliminates the enzyme from cell free preparations that may compete with a biosynthetic pathway developed from lysed preparations.
- An "enzyme” means any substance, typically composed wholly or largely of amino acids making up a protein or polypeptide that catalyzes or promotes, more or less specifically, one or more chemical or biochemical reactions .
- a “protein” or “polypeptide”, which terms are used interchangeably herein, comprises one or more chains of chemical building blocks called amino acids that are linked together by chemical bonds called peptide bonds.
- a protein or polypeptide can function as an enzyme.
- the term “metabolically engineered” or “metabolic engineering” involves rational pathway design and assembly of biosynthetic genes, genes associated with operons, and control elements of such polynucleotides, for the production of a desired metabolite, such as an acetyl-phosphate and/or acetyl-CoA, higher alcohols or other chemical, in a microorganism.
- a desired metabolite such as an acetyl-phosphate and/or acetyl-CoA, higher alcohols or other chemical
- “Metabolically engineered” can further include optimization of metabolic flux by regulation and optimization of transcription, translation, protein stability and protein functionality using genetic engineering and appropriate culture condition including the reduction of, disruption, or knocking out of, a competing metabolic pathway that competes with an intermediate leading to a desired pathway.
- a biosynthetic gene can be heterologous to the host microorganism, either by virtue of being foreign to the host, or being modified by mutagenesis, recombination, and/or association with a heterologous expression control sequence in an endogenous host cell.
- the polynucleotide can be codon optimized.
- a “metabolite” refers to any substance produced by metabolism or a substance necessary for or taking part in a particular metabolic process that gives rise to a desired
- a metabolite can be an organic compound that is a starting material (e.g., glucose etc.), an intermediate in (e.g., acetyl-coA) , or an end product (e.g., CBDA) of metabolism.
- Metabolites can be used to construct more complex molecules, or they can be broken down into simpler ones.
- Intermediate metabolites may be synthesized from other metabolites, perhaps used to make more complex substances, or broken down into simpler compounds, often with the release of chemical energy.
- a “mutation” means any process or mechanism resulting in a mutant protein, enzyme, polynucleotide, gene, or cell. This includes any mutation in which a protein, enzyme, polynucleotide, or gene sequence is altered, and any detectable change in a cell arising from such a mutation. Typically, a mutation occurs in a polynucleotide or gene sequence, by point mutations, deletions, or insertions of single or multiple nucleotide residues.
- a mutation includes polynucleotide alterations arising within a protein encoding region of a gene as well as alterations in regions outside of a protein-encoding sequence, such as, but not limited to, regulatory or promoter sequences.
- a mutation in a gene can be "silent", i.e., not reflected in an amino acid alteration upon expression, leading to a "sequence-conservative" variant of the gene. This generally arises when one amino acid corresponds to more than one codon.
- a mutation that gives rise to a different primary sequence of a protein can be referred to as a mutant protein or protein variant.
- polynucleotide, gene, or cell means a protein, enzyme,
- a "parental microorganism” refers to a cell used to generate a recombinant microorganism.
- microorganism describes, in one embodiment, a cell that occurs in nature, i.e. a "wild-type” cell that has not been genetically modified.
- the term "parental microorganism” further describes a cell that serves as the "parent” for further engineering. In this latter embodiment, the cell may have been genetically engineered, but serves as a source for further genetic engineering.
- a wild-type microorganism can be any suitable microorganism.
- a wild-type microorganism can be any suitable microorganism.
- a first target enzyme such as a hexokinase.
- This microorganism can act as a parental microorganism in the generation of a microorganism modified to express or over-express a second target enzyme e.g., a fructose-1 , 6-bisphosphate aldolase.
- a second target enzyme e.g., a fructose-1 , 6-bisphosphate aldolase.
- that microorganism can be modified to express or over express e.g., an NADH oxidase and a Gald-3-phosphate dehydrogenase (and mutants thereof) , which can be further modified to express or over express a third target enzyme, e.g., a phosphoglycerate kinase etc.
- express or “over express” refers to the phenotypic expression of a desired gene product.
- a naturally occurring gene in the organism can be engineered such that it is linked to a heterologous promoter or regulatory domain, wherein the regulatory domain causes expression of the gene, thereby modifying its normal expression relative to the wild-type organism.
- the organism can be engineered to remove or reduce a repressor function on the gene, thereby modifying its expression.
- a cassette comprising the gene sequence operably linked to a desired expression control/regulatory element is engineered in to the microorganism.
- a parental microorganism functions as a reference cell for successive genetic modification events.
- Each modification event can be accomplished by introducing one or more nucleic acid molecules into the reference cell.
- the introduction facilitates the expression or over-expression of one or more target enzyme or the reduction or elimination of one or more target enzymes.
- the term “facilitates” encompasses the activation of endogenous polynucleotides encoding a target enzyme through genetic modification of e.g., a promoter sequence in a parental microorganism. It is further understood that the term “facilitates" encompasses the introduction of exogenous
- generating metabolites including homologs, variants, fragments, related fusion proteins, or functional equivalents thereof are used in recombinant nucleic acid molecules that direct the expression of such polypeptides in appropriate host cells, such as bacterial or yeast cells.
- appropriate host cells such as bacterial or yeast cells.
- sequence listing appended hereto provide exemplary polypeptides useful in the methods described herein. It is understood that the addition of sequences which do not alter the activity of a polypeptide molecule, such as the addition of a non functional or non-coding sequence (e.g., polyHIS tags), is a conservative variation of the basic molecule.
- recombinant nucleic acid refers to polynucleotides such as deoxyribonucleic acid (DNA) , and, where appropriate, ribonucleic acid (RNA) .
- polynucleotide and, as appropriate, translation of the resulting mRNA transcript to a protein or polypeptide.
- expression of a protein or polypeptide results from transcription and translation of the open reading frame .
- polypeptide can typically tolerate one or more amino acid
- the disclosure includes such polypeptides with alternate amino acid sequences, and the amino acid sequences encoded by the DNA sequences shown herein merely illustrate exemplary embodiments of the disclosure.
- the disclosure provides polynucleotides in the form of recombinant DNA expression vectors or plasmids, as described in more detail elsewhere herein, that encode one or more target enzymes.
- such vectors can either replicate in the cytoplasm of the host microorganism or integrate into the
- the vector can be a stable vector (i.e., the vector remains present over many cell divisions, even if only with selective pressure) or a transient vector (i.e., the vector is gradually lost by host microorganisms with increasing numbers of cell divisions) .
- the disclosure provides DNA molecules in isolated (i.e., not pure, but existing in a preparation in an abundance and/or concentration not found in nature) and purified (i.e., substantially free of contaminating materials or substantially free of materials with which the corresponding DNA would be found in nature) form.
- a polynucleotide of the disclosure can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques and those procedures described in the Examples section below.
- the nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
- nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
- the disclosure provides a number of polypeptide sequences in the sequence listing accompanying the present application, which can be used to design, synthesize and/or isolate polynucleotide sequences using the degeneracy of the genetic code or using publicly available databases to search for the coding sequences .
- an isolated polynucleotide molecule encoding a polypeptide homologous to the enzymes described herein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence encoding the particular polypeptide, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into the
- polynucleotide by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. In contrast to those positions where it may be desirable to make a non-conservative amino acid substitution, in some positions it is preferable to make conservative amino acid substitutions.
- Optimized coding sequences containing codons preferred by a particular prokaryotic or eukaryotic host can be prepared, for example, to increase the rate of translation or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, as compared with transcripts produced from a non- optimized sequence.
- Translation stop codons can also be modified to reflect host preference. For example, typical stop codons for S. cerevisiae and mammals are UAA and UGA, respectively. The typical stop codon for monocotyledonous plants is UGA, whereas insects and E.
- substrate or “suitable substrate” refers to any substance or compound that is converted or meant to be converted into another compound by the action of an enzyme.
- the term includes not only a single compound, but also combinations of compounds, such as solutions, mixtures and other materials which contain at least one substrate, or derivatives thereof.
- substrate encompasses not only compounds that provide a starting material, but also intermediate and end product
- Transformation refers to the process by which a vector is introduced into a host cell. Transformation (or transduction, or transfection) , can be achieved by any one of a number of means including electroporation, microinjection, biolistics (or particle bombardment-mediated delivery) , or agrobacterium mediated
- a "vector” generally refers to a polynucleotide that can be propagated and/or transferred between organisms, cells, or cellular components.
- Vectors include viruses, bacteriophage, pro viruses, plasmids, phagemids, transposons, and artificial
- chromosomes such as YACs (yeast artificial chromosomes), BACs (bacterial artificial chromosomes), and PLACs (plant artificial chromosomes), and the like, that are "episomes, " that is, that replicate autonomously or can integrate into a chromosome of a host cell.
- a vector can also be a naked RNA polynucleotide, a naked DNA polynucleotide, a polynucleotide composed of both DNA and RNA within the same strand, a poly-lysine-conjugated DNA or RNA, a peptide-conjugated DNA or RNA, a liposome-conjugated DNA, or the like, that are not episomal in nature, or it can be an organism which comprises one or more of the above polynucleotide constructs such as an agrobacterium or a bacterium.
- an expression vector can vary widely, depending on the intended use of the vector and the host cell(s) in which the vector is intended to replicate or drive expression.
- Expression vector components suitable for the expression vector can vary widely, depending on the intended use of the vector and the host cell(s) in which the vector is intended to replicate or drive expression.
- suitable promoters for inclusion in the expression vectors of the disclosure include those that function in eukaryotic or prokaryotic host microorganisms. Promoters can comprise regulatory sequences that allow for regulation of expression relative to the growth of the host microorganism or that cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus.
- suitable promoters for inclusion in the expression vectors of the disclosure include those that function in eukaryotic or prokaryotic host microorganisms. Promoters can comprise regulatory sequences that allow for regulation of expression relative to the growth of the host microorganism or that cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus.
- promoters derived from genes for biosynthetic enzymes, antibiotic-resistance conferring enzymes, and phage proteins can be used and include, for example, the galactose, lactose (lac) , maltose, tryptophan (trp) , beta- lactamase (bla) , bacteriophage lambda PL, and T5 promoters.
- synthetic promoters such as the tac promoter (U.S. Pat. No. 4,551,433, which is incorporated herein by reference in its entirety), can also be used.
- E. coli expression vectors it is useful to include an E. coil origin of replication, such as from pUC, plP, pi, and pBR.
- recombinant expression vectors contain at least one expression system, which, in turn, is composed of at least a portion of a gene coding sequences operably linked to a promoter and optionally termination sequences that operate to effect expression of the coding sequence in compatible host cells.
- the host cells are modified by transformation with the recombinant DNA expression vectors of the disclosure to contain the expression system sequences either as extrachromosomal elements or integrated into the chromosome.
- homologs used with respect to an original enzyme or gene of a first family or species refers to distinct enzymes or genes of a second family or species which are determined by functional, structural or genomic analyses to be an enzyme or gene of the second family or species which corresponds to the original enzyme or gene of the first family or species. Most often, homologs will have
- homologs of an enzyme or gene can readily be cloned using genetic probes and PCR. Identity of cloned sequences as homolog can be confirmed using functional assays and/or by genomic mapping of the genes.
- a protein has "homology” or is “homologous” to a second protein if the nucleic acid sequence that encodes the protein has a similar sequence to the nucleic acid sequence that encodes the second protein.
- a protein has homology to a second protein if the two proteins have "similar” amino acid sequences. (Thus, the term “homologous proteins” is defined to mean that the two proteins have similar amino acid sequences) .
- two proteins are substantially homologous when the amino acid sequences have at least about 30%, 40%, 50% 60%, 65%, 70%, 75%,
- the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes) .
- the length of a reference sequence aligned for comparison purposes is at least 30%, typically at least 40%, more typically at least 50%, even more typically at least 60%, and even more typically at least 70%, 80%, 90%, 100% of the length of the reference sequence.
- amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
- a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity” is equivalent to amino acid or nucleic acid "homology") .
- the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
- the percent sequence identity or degree of homology may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art (see, e.g., Pearson et al . , 1994, hereby incorporated herein by reference) .
- isozymes can be used that carry out the same functional conversion/reaction, but which are so
- a "conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
- Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine) , nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan) , beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, his
- the following six groups each contain amino acids that are conservative substitutions for one another: 1) Serine (S) , Threonine (T) ; 2) Aspartic Acid (D) , Glutamic Acid (E) ; 3) Asparagine (N) , Glutamine (Q) ; 4) Arginine (R) , Lysine (K) ; 5) Isoleucine (I) , Leucine (L) , Methionine (M) , Alanine (A) , Valine (V) , and 6) Phenylalanine (F) , Tyrosine (Y) , Tryptophan (W) .
- Sequence homology for polypeptides is typically measured using sequence analysis software. See, e.g., the Sequence Analysis Software Package of the Genetics Computer Group (GCG) , University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wis. 53705. Protein analysis software matches similar sequences using measure of homology assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as "Gap” and "Bestfit” which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, e.g., GCG Version 6.1.
- BLASTp Typical parameters for BLASTp are: Expectation value: 10 (default) ; Filter: seg (default) ; Cost to open a gap: 11 (default) ; Cost to extend a gap: 1 (default) ; Max. alignments: 100 (default) ; Word size: 11 (default) ; No. of descriptions: 100 (default); Penalty Matrix: BLOWSUM62.
- polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1.
- FASTA provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, 1990, hereby incorporated herein by reference) .
- percent sequence identity between amino acid sequences can be determined using FASTA with its default parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1, hereby incorporated herein by reference.
- accession numbers and sequences for various genes, homologs and variants useful in the generation of recombinant microorganism and proteins for use in in vitro systems It is to be understood that homologs and variants described herein are exemplary and non-limiting. Additional homologs, variants and sequences are available to those of skill in the art using various databases including, for example, the
- NCBI National Center for Biotechnology Information
- microorganisms can be modified to include all or part of a recombinant metabolic pathway suitable for the production of prenylated compounds or cannabinoids or cannabinoid precursors. It is also understood that various microorganisms can act as "sources" for genetic material encoding target enzymes suitable for use in a recombinant microorganism provided herein.
- RNA polymerase mediated techniques e.g., NASBA
- RNA can be converted into a double stranded DNA suitable for restriction digestion, PCR expansion and sequencing using reverse transcriptase and a polymerase. See, e.g., Ausubel, Sambrook and Berger, all supra.
- Corynebacterium glutamicum catalase were purchased from Sigma Aldrich. Aerococcus viridians pyruvate oxidase was purchased from A.G. scientific. All cofactors and reagents were purchased from either Sigma Aldrich or Thermo Fisher Scientific, with the exception of olivetolic acid, which was purchased from Santa Cruz Biotechnology and divarinic acid, which was purchased from Toronto Research Chemicals.
- the NphB gene was purchased as a gene block from IDT DNA, and cloned into a pET 28 (+) vector using the Gibson Assembly method. The remaining enzymes were amplified from genomic DNA or a plasmid, and cloned into pET28 (+) using the same Gibson assembly method. All plasmids were transformed into BL21 (DE3) Gold, and enzymes expressed in LB media with 50 pg/mL kanamycin. 1 L cultures were inoculated with 2 mL of a saturated culture in the same media, and grown to an ODeoo of 0.5 - 0.8 at 37 °C.
- the cultures were induced with 1 mM IPTG, and expressed at 18 °C for 16 hours.
- the cells were harvested by centrifugation at 2,500 x g, and resuspended in ⁇ 20 mL lysis buffer: 50 mM Tris [pH 8.0], 150 mM NaCl, and 10 mM imidazole.
- the cells were lysed using an Emulsiflex instrument.
- the lysate was clarified by centrifugation at 20,000 x g, and the supernatant was batch bound to 1 mL NiNTA resin for 30 mins at 4 °C.
- the resin was transferred to a gravity flow column.
- the resin was washed with 10 column volumes of wash buffer: 50 mM Tris [pH 8.0], 150 mM NaCl, and 10 mM imidazole.
- the protein was then eluted with 2 column volumes of elution buffer: 50 mM Tris [pH 8.0], 150 mM NaCl, 250 mM imidazole and 30% (v/v) glycerol.
- Enzymes were flash frozen in elution buffer using liquid N2, and the enzyme stocks were stored at -80 °C.
- PDH Cell-free Reactions The PDH reactions were assembled in two parts. First the co-factors and substrates were combined in one tube, and the enzymes were combined in another.
- the reactions were initiated by mixing the co-factors and enzymes in a final volume of 200 pL .
- the final substrate and co-factor concentrations were as follows: 500 mM glucose, 1 mM 1,6 fructose bisphosphate , 4 mM ATP, 0.5 mM 2,3 bisphosphoglycerate , 0.5 mM
- NAD + 1.5 mM CoA, 1.5 mM NADP + , 0.5 mM TPP, 6 mM MgCl 2 , 10 mM KC1,
- PDH Activity Assays PDH was assayed for activity in the presence of several aromatic polyketides.
- the vehicle control was 1% ethanol, and the activity was compared to an assay without the aromatic polyketides.
- the final reaction volume was 200 pL, and contained 2 mM NAD + , 2 mM CoA, 1 mM TPP, 5 mM MgCl 2 , 5 mM KC1, 50 mM Tris pH 8.0, and 5 pL of 1.25 mg/mL PDH.
- the reactions were set up in a 96-well plate.
- the aromatic polyketides were added to a final concentration of 1 mM and the ethanol control was added to a final concentration of 1% (v/v) .
- the plate was incubated at room
- RgOc/PTA Cell-free Reactions The PyOx/PTA reactions were assembled in two pieces. First the co-factors and substrates were combined in one tube, and the enzymes were combined in another. The final co-factor and substrate concentrations in the 200 pL reaction were as follows: 500 mM glucose, 1 mM 1,6 fructose bisphosphate , 4 mM ATP, 0.5 mM 2,3 bisphosphoglycerate , 0.5 mM
- NAD + 1.5 mM CoA, 3 mM mM NADP + , 0.5 mM TPP, 6 mM MgCl 2 , 10 mM KC1, 50 mM Tris pH 8.0 and 50 mM phosphate buffer [pH 8.0] .
- the amount of enzyme added to each reaction is detailed in Table 3. The co factors and enzymes were mixed to initiate the reaction, and a 500 pL nonane overlay was added to the top. The reactions were incubated at room temperature shaking gently on a gel shaker.
- 1,6 DHN / 5-p-l,6 DHN When the aromatic substrate was the varied component 0.5 to 5 mM of the aromatic substrate was added to the reaction, and the reactions were quenched at 24 hours. When time was the varied component, 5 mM of 1, 6 DHN was added, and separate reactions were quenched at ⁇ 12, 24, 48 and 72 hours.
- cannabinoid pathway showed that the same titers could be achieved with less glucose, so the glucose concentration was reduced to 150 mM. Additionally, increasing the NADP + concentration to 6 mM and decreasing the ATP concentration to 1 mM led to higher titers of CBGA. The olivetolate concentration was set at 5 mM. The amount of NphB added to the reaction was variable. The data shown in Figure 2c utilized 1.5 mg/mL NphB, and the reactions were quenched at ⁇ 4, 8, 14, 24, 48, 72 and 96 hours. The data shown in Figure 4a was achieved with 0.5 mg/mL of WT NphB and M23, and reactions were quenched at ⁇ 6, 9, 12, 24, 48, 72 and 96 hours.
- the final concentration of the prenyl-trans ferase was 1 mg/mL, and we tested AtaPT, NovQ, and NphB with apigenin, daidzein, genistein, naringenin, and resveratrol. We also tested NphB with olivetol, olivetolate, and 1,6 DHN. The reactions were quenched at 24 h.
- the reaction vial was washed with 200 pL of ethyl acetate, which was then pooled with the reaction in the microcentrifuge tube.
- the samples were vortexed for 5-10 seconds and then centrifuged for 3 minutes at 13,000 rpm.
- the organic layer was removed, and the remaining aqueous layer was extracted 2 additional times with 200 pL of ethyl acetate. For each sample the organic extract was pooled, and then evaporated using a vacuum centrifuge. The samples were re-dissolved in methanol for HPLC analysis .
- CBDA cannabinoids
- CBDVA cannabinoids
- prenyl-products prenyl-apigenin, prenyl-daidzein, prenyl-naringenin, prenyl- genistein, prenyl-resveratrol, and prenyl-olivetol
- the prenyl- products were quantified based on substrate consumption.
- serial dilutions of each aromatic substrate were subjected to the reaction mix, but to prevent product formation the prenyl-transferase was left out.
- Liquid chromatography-mass spectrometry was used to quantify the amount of substrate consumed by the reaction compared to the standard curve.
- Electrospray ionisation time-of-flight measurements were carried out on a Waters LCT-Premier XE Time of Flight Instrument controlled by MassLynx 4.1 software (Waters Corporation, Milford, MA) .
- the instrument was equipped with the Multi Mode Ionization source operated in the electrospray mode.
- a solution of Leucine Enkephalin (Sigma Chemical, L9133) was used in the Lock-Spray to obtain accurate mass measurements.
- Samples were infused using direct loop injection on a Waters Acquity UPLC system. Samples were separated on a Waters Acquity UPLC system using an Acquity BEH C18 1.7 pm column (50 c 2.1 mm) and were eluted with a gradient of SO PS! solvent B over 10 min (solvent A: water, solvent B:
- NMR Spectroscopy was used to identify prenyl-products, and quantify 5-p-l,6-DHN.
- 1,6 DHN/ 5-p-l,6 DHN The PyOx/PTA cell-free system was used to produce prenyl-DHN. 200 pL reactions were pooled, and extracted 3 times with an equivalent amount of nonane and then the nonane was evaporated. The product of the reactions was suspended in 500 pL of deuterated methanol (CD 3 OD) , with 2 mM 1,3,5- trimethoxybenzene (TMB) as an internal standard. Spectra were collected on an AV400 Bruker NMR spectrometer. The amount of the prenylated compound in the sample was determined with reference to the internal TMB standard. The proton signal from TMB (3H, s) at 6.05 ppm were compared with an aromatic proton corresponding to 5- p-l,6-DHN (1H, d) at 7.27 ppm.
- TMB deuterated methanol
- TMB 1,3,5- trimethoxybenzene
- NMR NMR was also used to identify the product of the enzymatic system with divarinic acid as the aromatic substrate.
- the PyOx/PTA system was set up as detailed above, and the reactions were quenched at 24 hours.
- the reactions were extracted as detailed above, and analyzed on the HPLC. There was a new major peak at 6.7 minutes that was predicted to be the prenylated divarinic acid.
- the HPLC peak was purified, removed the solvent, and re-dissolved the pure component in 600 pL of CD 3 OD.
- a proton spectrum collected with an AV500 Bruker NMR spectrometer was compared to a proton spectrum published by Shoyama et al.
- the olivetolic acid was placed in 6 different positions in the active site with the plane of the olivetolate aromatic ring parallel to the GST alkyl tail and the desired prenylation site 3.7 angstroms away from the eventual carbocation mirroring the placement of DHN in the 1ZB6 crystal structure.
- Residues 49, 162, 213, 224, 232, 233, 234, 271, 286, and 288 were allowed to be any amino acid during the Rosetta design with other sidechains held in a fixed position and the backbone fixed.
- the designed residues were in direct contact with the olivetolate and not in direct contact with GST.
- the fixed backbone script The fixed backbone script
- the pellets were re-suspended in 500 pL of lysis buffer: 50 mM [Tris pH 8.0], 150 mM NaCl, and 5 mM imidazole and lysed by sonication.
- the cell lysate was clarified by centrifugation at 20,000 x g for 10 minutes at 4°C, and the supernatant was incubated at 4°C with 50 pL of NiNTA resin.
- a 96-well spin column plate was used to purify the NphB constructs. The supernatant/resin was applied to the column and centrifuged for 2 mins at 500 x g.
- lysis buffer 500 pL was then added, and the plate was centrifuged again for 1 minute at 500 x g.
- the protein was eluted using 200 pL of elution buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 250 mM imidazole and 30% (v/v) glycerol) .
- the enzymes were assayed under the following conditions: 2.5 mM geranyl pyrophosphate, 5 mM olivetolate, 5 mM MgCl , 50 mM Tris pH 8.0, ⁇ 0.1 mg/mL NphB mutant in a final volume of 100 pL .
- Enzyme Kinetic Parameters The reactions were set up under the following conditions: 50 mM Tris [pH 8.0], 2.5 mM GPP, 5 mM MgC]_2, ⁇ 27 mM enzyme, and olivetolate or divarinic acid was varied from 0.1 mM to 6 mM in a final volume of 200 pL . 40 pL of the reaction was quenched in 80 m ⁇ acetonitrile + 0.1% TFA, at the time intervals detailed below. The reactions were centrifuged for 5 minutes at 13,000-16,060 x g to pellet the protein, and the supernatant was analyzed using the HPLC method detailed above.
- the initial rate was plotted vs the concentration of substrate, and fit with the Michaelis-Menten equation to determine the kinetic parameters k cat and K M (OriginPro) .
- Each Michaelis-Menten curve was performed in triplicate. The average and standard deviation of the kinetic parameters are reported.
- the enzyme concentration for the mutants was ⁇ 27 mM, and the concentration of WT NphB was ⁇ 35 mM.
- Nonane-flow system for the extraction of CBGA from solution.
- a PyOx/PTA reaction was set up as detailed above.
- a 500 pL nonane overlay was added to the reaction in a 2 ml glass vial which was covered with 2 layers of breathable cell culture film.
- 2 needles were inserted into a 15 mL falcon tube at the -750 pL mark and the 3.5 mL mark.
- Luer locks to tubing connectors were connected to the needles and Viton tubing was connected to the other end of the luer lock. Needles were connected to the other end of the tubing via a luer lock connector and inserted through the mesh covering so they were only touching the nonane layer and not the reaction.
- CBDAS Cloning CBDAS .
- a gene block of CBDAS was ordered from IDT codon optimized for Pichia pastoris .
- the signal sequence was removed by PCR amplifying from the 28 th residue of the protein sequence (NPREN%) through the end of the protein, with overhangs compatible with the pPICZa vector.
- the PCR product was cloned into the pPICZa vector digested with EcoRI and Xbal using the Gibson cloning method.
- the product of the assembly reaction was
- the plasmid was transformed into BL21 Gold (DE3) cells a clone with the correct sequence isolated.
- the plasmid was digested with Pmel for 2 hours, and then purified using the Qiagen PCR purification protocol.
- the plasmid was transformed into Pichia pastoris X33 using
- the colonies were re-suspended in 15 pL of sterile water and 5 pL of the resuspended colony was transferred into a PCR tube with 0.2% SDS. The samples were heated for 10 minutes at 99°C, and then 1 pL was used as the template for PCR.
- CBDAS Expression Test The six colonies were grown overnight at 30°C to obtain a saturated culture. The overnight cultures were used to inoculate a 25 mL culture in BMGY media and grown to an OD of -2. The cells were harvested by centrifugation at 2,000 x g for 10 minutes. The cell pellet was re-suspended in 90 mL of BMMY media, and incubated at 30°C for 5 days. Each day, 1 mL of the culture was removed for SDS-PAGE analysis, and 500 pL of methanol was added. On day 3 the cultures were screened for CBDAS activity.
- the assay conditions were as follows: 100 pL of 200 mM citrate buffer, 100 pM CBGA, 5 mM MgCl2, 5 mM KC1, 1 mM FAD and 50 pL of the expression media in a final volume of 200 pL .
- the reactions were incubated overnight at room temperature and then extracted 3 times with 200 pL of ethyl acetate.
- the ethyl acetate extractions were pooled for each sample, and removed using a vacuum centrifuge.
- the samples were re-suspended in 200 pL of methanol and analyzed by HPLC. All clones produced active CBDAS.
- CBGA / CBDA A PyOx/PTA enzymatic system was set up as detailed above to produce CBGA. After 24 hours 200 pL of the nonane overlay from the CBGA reaction was transferred to a CBDAS reaction vessel. In the aqueous layer: 50 mM Hepes [pH 7.0], 5 mM MgCl , 5 mM KC1, 25 mM FAD, 0.1 mg/mL CBDAS concentrate. The reaction was incubated at 30°C with gentle shaking. Reactions were quenched at 12, 24, 48, 72 and 96 hours.
- CBGVA / CBDVA HPLC purified CBGVA was converted to CBDVA.
- the final reaction volume was 200 pL, with 50 mM Hepes [pH 7.0], 5 mM MgCl , 5 mM KC1, 25 mM FAD and 0.1 mg/mL (total protein) of CBDAS concentrate.
- a 200 pL nonane overlay was added, and the reactions were incubated at 30 °C with gentle shaking. The reactions were quenched at ⁇ 24, 48, 72 and 96 hours.
- MatB Activity Assay A coupled enzymatic assay was used to determine the activity of malonyl-CoA synthetase (MatB) from R. palustris (see, e.g., SEQ ID NO: 82-83) in the presence of OA and DA.
- the reaction conditions were: 2.5 mM malonate, 2 mM ATP, 1 mM CoA, 2.5 mM phosphoenolpyruvate (PEP), 1 mM NADH, 5 mM MgCl , 10 mM KC1, 0.35 mg/mL ADK, 0.75 pg/mL MatB, 1.6 units of PK and 2.5 units of LDH, and 50 mM Tris [pH 8.0] .
- Background ATPase activity was controlled for by leaving out the substrate (malonate) , and either 1% ethanol, 250 mM or 5 mM OA or 5 mM DA was added to the remaining reactions.
- the activity of MatB was determined by monitoring decreasing absorbance at 340 nm due to NADH consumption using an M2 SpectraMax. To ensure that MatB was limiting at 5 mM OA or DA, MatB was doubled to 1.5 pg/mL. The rate of the reaction doubled suggesting that MatB was the limiting component in the system. The rate of NADH consumption at 5 mM OA and 5 mM DA was normalized to the 1% ethanol control.
- AAE3 Activity Assay A coupled enzymatic assay, similar to the one above was used to determine the activity of acyl activating enzyme 3 (AAE3) (see, e.g., SEQ ID NOs : 70-71 and homologs - SEQ ID NO: 72-75) in the presence of OA and DA.
- the conditions were the same as the MatB assay with the following modifications: 2.5 mM hexanoate was added in lieu of malonate, and 15 pg/mL of AAE3 was added in lieu of MatB.
- AAE3 was doubled in the presence of 5 mM OA or DA. The rate of the reaction doubled indicating AAE3 is limiting.
- ADK Activity Assay A coupled enzymatic assay was used to determine the activity of adenylate kinase (ADK) (see, e.g. , SEQ
- CPK Activity Assay A coupled enzymatic assay was used to determine the activity of creatine kinase (CPK) in the presence of OA or DA.
- the reaction conditions were: 5 mM Creatine Phosphate,
- OLS Activity Assay Olivetol synthase (OLS) (see, e.g., SEQ ID NO: 76-77) was assayed by setting up the following
- OLS/OAC Activity Assay To produce OA, the same OLS conditions specified above were used, but olivetolic acid cyclase (OAC) (see, e.g., SEQ ID NO:78-79) was added to the reaction at 0.6 mg/mL. The reactions were quenched and analyzed in the same manner as the OLS assay. Acetyl-phosphate and BSA were added to the assays individually 5mM - 40 mM AcP and 10 - 30 mg/mL BSA final
- the reactions were initiated by the addition of the enzymes listed in Table 6. The reaction was incubated overnight at room temperature, and the reaction was quenched and extracted 3 times with 200 pL of ethyl acetate. The ethyl acetate was removed using a vacuum centrifuge. The sample was dissolved in 200 pL of methanol and analyzed using HPLC.
- the enzymes for the MdcA path can be found in Table 7.
- the MdcA reaction was set up under the same cofactor conditions specified above with the following changes: 3 mM ATP, 0.25 mM AMP, 25 mM creatine phosphate and no Tris buffer.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2021001065A MX2021001065A (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds. |
JP2021504498A JP2021532747A (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for producing cannabinoids and other prenylated compounds |
SG11202100725YA SG11202100725YA (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
CN201980063307.7A CN112789505B (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platforms for the production of cannabinoids and other prenylated compounds |
CA3107544A CA3107544A1 (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
AU2019314484A AU2019314484A1 (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
US17/264,758 US11479760B2 (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
EP19843397.1A EP3830581A4 (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
KR1020217005261A KR20210049805A (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform to produce cannabinoids and other prenylated compounds |
BR112021001450-0A BR112021001450A2 (en) | 2018-08-01 | 2019-08-01 | recombinant polypeptide, recombinant pathway, method for producing a prenylated compound, cell-free enzyme system for the production of geranyl pyrophosphate, isolated polynucleotide, vector, and recombinant microorganism |
IL280442A IL280442A (en) | 2018-08-01 | 2021-01-27 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
US18/049,221 US20230193221A1 (en) | 2018-08-01 | 2022-10-24 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862713348P | 2018-08-01 | 2018-08-01 | |
US62/713,348 | 2018-08-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/264,758 A-371-Of-International US11479760B2 (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
US18/049,221 Continuation US20230193221A1 (en) | 2018-08-01 | 2022-10-24 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020028722A1 true WO2020028722A1 (en) | 2020-02-06 |
WO2020028722A9 WO2020028722A9 (en) | 2020-04-09 |
Family
ID=69232031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/044752 WO2020028722A1 (en) | 2018-08-01 | 2019-08-01 | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
Country Status (12)
Country | Link |
---|---|
US (2) | US11479760B2 (en) |
EP (1) | EP3830581A4 (en) |
JP (1) | JP2021532747A (en) |
KR (1) | KR20210049805A (en) |
CN (1) | CN112789505B (en) |
AU (1) | AU2019314484A1 (en) |
BR (1) | BR112021001450A2 (en) |
CA (1) | CA3107544A1 (en) |
IL (1) | IL280442A (en) |
MX (1) | MX2021001065A (en) |
SG (1) | SG11202100725YA (en) |
WO (1) | WO2020028722A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111286509A (en) * | 2020-03-20 | 2020-06-16 | 天津法莫西生物医药科技有限公司 | Alkene reductase mutant and coding gene and application thereof |
WO2021067748A1 (en) * | 2019-10-03 | 2021-04-08 | Renew Biopharma, Inc. | Compositions and methods for using genetically modified orthologous enzymes |
CN113355300A (en) * | 2020-08-05 | 2021-09-07 | 深圳蓝晶生物科技有限公司 | Aromatic isopentenyl transferase mutant, construction method of recombinant bacterium for expression of mutant and recombinant bacterium constructed by mutant |
EP3901256A1 (en) * | 2020-04-21 | 2021-10-27 | Synbionik GmbH | Optimized production of cbga from olivetol acid and geranyl pyrophosphate via synnphb |
US11274320B2 (en) | 2019-02-25 | 2022-03-15 | Ginkgo Bioworks, Inc. | Biosynthesis of cannabinoids and cannabinoid precursors |
WO2022251285A1 (en) | 2021-05-26 | 2022-12-01 | Invizyne Technologies, Inc. | Prenyltransferase variants with increased thermostability |
EP4263843A4 (en) * | 2020-12-18 | 2024-07-10 | Debut Biotechnology Inc | Cell-free production of geranyl pyrophosphate from glycerol in a cell-free manufacturing system |
EP4081646A4 (en) * | 2019-12-26 | 2024-07-17 | Univ California | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
US12043859B2 (en) | 2019-01-30 | 2024-07-23 | Genomatica, Inc. | Recovery, decarboxylation, and purification of cannabinoids from engineered cell cultures |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021001450A2 (en) * | 2018-08-01 | 2021-04-27 | The Regents Of The University Of California | recombinant polypeptide, recombinant pathway, method for producing a prenylated compound, cell-free enzyme system for the production of geranyl pyrophosphate, isolated polynucleotide, vector, and recombinant microorganism |
WO2020247741A1 (en) * | 2019-06-06 | 2020-12-10 | Genomatica, Inc. | Olivetolic acid cyclase variants and methods for their use |
CN113584089B (en) * | 2021-07-01 | 2023-11-24 | 嘉兴欣贝莱生物科技有限公司 | Application of isopentenyl transferase in catalytic synthesis of cannabigerol or cannabigerol acid |
CN114621982B (en) * | 2022-03-16 | 2023-11-07 | 嘉兴欣贝莱生物科技有限公司 | Biosynthesis method of geranyl diphosphate and application of geranyl diphosphate in preparation of cannabis compounds |
CN116024111A (en) * | 2022-12-03 | 2023-04-28 | 中国科学院深圳先进技术研究院 | Microbial cell for producing cannabigerol, and construction method and application thereof |
CN116622784B (en) * | 2023-02-14 | 2024-03-01 | 黑龙江八一农垦大学 | Application of cannabidiol synthase |
CN117363593B (en) * | 2023-11-14 | 2024-07-09 | 北京大学深圳研究生院 | Multienzyme cascade catalytic system and application thereof in enantiomer-kaurene synthesis |
CN117512033B (en) * | 2023-12-21 | 2024-04-19 | 山东三元生物科技股份有限公司 | Method for simultaneously producing D-tagatose and D-psicose from glucose |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100285502A1 (en) * | 2005-01-28 | 2010-11-11 | The Salk Institute For Biological Studies Toudai Tlo, Ltd. | Novel aromatic prenyltransferases, nucleic acids encoding same and uses therefor |
WO2019173770A1 (en) * | 2018-03-08 | 2019-09-12 | Genomatica, Inc. | Prenyltransferase variants and methods for production of prenylated aromatic compounds |
WO2019183152A1 (en) * | 2018-03-19 | 2019-09-26 | Renew Biopharma, Inc. | Compositions and methods for using genetically modified enzymes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2204300B1 (en) * | 2002-07-18 | 2005-05-01 | J. URIACH & CIA S.A. | NEW DERIVATIVES OF 2,4-DIHYDROXIBENZOIC ACID. |
DE102010011601A1 (en) | 2010-03-16 | 2011-09-22 | Eberhard-Karls-Universität Tübingen | New prenyltransferase from fungi, where its enzymatic activity is independent in the presence of magnesium ions, useful for the biotechnological production of prenylated compounds, e.g. 3-dimethylallyl-2,7-dihydroxynaphthalene |
EP3325634A4 (en) * | 2015-07-21 | 2019-03-13 | The Regents of The University of California | Glucose metabolism with molecular purge valve |
AU2018256863B2 (en) | 2017-04-27 | 2024-06-06 | Regents Of The University Of California | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives |
BR112021001450A2 (en) * | 2018-08-01 | 2021-04-27 | The Regents Of The University Of California | recombinant polypeptide, recombinant pathway, method for producing a prenylated compound, cell-free enzyme system for the production of geranyl pyrophosphate, isolated polynucleotide, vector, and recombinant microorganism |
CA3136629A1 (en) | 2019-04-12 | 2020-10-15 | Renew Biopharma, Inc. | Compositions and methods for using genetically modified enzymes |
CN113355300B (en) | 2020-08-05 | 2022-04-01 | 深圳蓝晶生物科技有限公司 | Aromatic isopentenyl transferase mutant, construction method of recombinant bacterium for expression of mutant and recombinant bacterium constructed by mutant |
-
2019
- 2019-08-01 BR BR112021001450-0A patent/BR112021001450A2/en not_active Application Discontinuation
- 2019-08-01 CN CN201980063307.7A patent/CN112789505B/en active Active
- 2019-08-01 JP JP2021504498A patent/JP2021532747A/en active Pending
- 2019-08-01 SG SG11202100725YA patent/SG11202100725YA/en unknown
- 2019-08-01 WO PCT/US2019/044752 patent/WO2020028722A1/en unknown
- 2019-08-01 KR KR1020217005261A patent/KR20210049805A/en unknown
- 2019-08-01 AU AU2019314484A patent/AU2019314484A1/en active Pending
- 2019-08-01 US US17/264,758 patent/US11479760B2/en active Active
- 2019-08-01 EP EP19843397.1A patent/EP3830581A4/en active Pending
- 2019-08-01 MX MX2021001065A patent/MX2021001065A/en unknown
- 2019-08-01 CA CA3107544A patent/CA3107544A1/en active Pending
-
2021
- 2021-01-27 IL IL280442A patent/IL280442A/en unknown
-
2022
- 2022-10-24 US US18/049,221 patent/US20230193221A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100285502A1 (en) * | 2005-01-28 | 2010-11-11 | The Salk Institute For Biological Studies Toudai Tlo, Ltd. | Novel aromatic prenyltransferases, nucleic acids encoding same and uses therefor |
WO2019173770A1 (en) * | 2018-03-08 | 2019-09-12 | Genomatica, Inc. | Prenyltransferase variants and methods for production of prenylated aromatic compounds |
WO2019183152A1 (en) * | 2018-03-19 | 2019-09-26 | Renew Biopharma, Inc. | Compositions and methods for using genetically modified enzymes |
Non-Patent Citations (4)
Title |
---|
See also references of EP3830581A4 * |
VALLIERE ET AL.: "A cell -free platform for the prenylation of natural products and application to cannabinoid production", NATURE COMMUNICATIONS, vol. 10, 4 February 2019 (2019-02-04), pages 565, XP055629791 * |
YANG ET AL.: "Catalytic Mechanism of Aromatic Prenylation by NphB", BIOCHEMISTRY, vol. 51, no. 12, 27 March 2012 (2012-03-27), pages 2606 - 2618, XP055683791, DOI: 10.1021/bi201800m * |
ZOCHER ET AL.: "Structure-Based Engineering Increased the Catalytic Turnover Rate of a Novel Phenazine Prenyltransferase", PLOS ONE, vol. 7, no. 10, 31 October 2012 (2012-10-31), pages e48427, XP055683807, DOI: 10.1371/journal.pone.0048427 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12043859B2 (en) | 2019-01-30 | 2024-07-23 | Genomatica, Inc. | Recovery, decarboxylation, and purification of cannabinoids from engineered cell cultures |
US11274320B2 (en) | 2019-02-25 | 2022-03-15 | Ginkgo Bioworks, Inc. | Biosynthesis of cannabinoids and cannabinoid precursors |
WO2021067748A1 (en) * | 2019-10-03 | 2021-04-08 | Renew Biopharma, Inc. | Compositions and methods for using genetically modified orthologous enzymes |
EP4081646A4 (en) * | 2019-12-26 | 2024-07-17 | Univ California | Biosynthetic platform for the production of cannabinoids and other prenylated compounds |
CN111286509A (en) * | 2020-03-20 | 2020-06-16 | 天津法莫西生物医药科技有限公司 | Alkene reductase mutant and coding gene and application thereof |
EP3901256A1 (en) * | 2020-04-21 | 2021-10-27 | Synbionik GmbH | Optimized production of cbga from olivetol acid and geranyl pyrophosphate via synnphb |
CN113355300A (en) * | 2020-08-05 | 2021-09-07 | 深圳蓝晶生物科技有限公司 | Aromatic isopentenyl transferase mutant, construction method of recombinant bacterium for expression of mutant and recombinant bacterium constructed by mutant |
EP4263843A4 (en) * | 2020-12-18 | 2024-07-10 | Debut Biotechnology Inc | Cell-free production of geranyl pyrophosphate from glycerol in a cell-free manufacturing system |
WO2022251285A1 (en) | 2021-05-26 | 2022-12-01 | Invizyne Technologies, Inc. | Prenyltransferase variants with increased thermostability |
US11518983B1 (en) | 2021-05-26 | 2022-12-06 | Invizyne Technologies, Inc. | Prenyltransferase variants with increased thermostability |
Also Published As
Publication number | Publication date |
---|---|
BR112021001450A2 (en) | 2021-04-27 |
AU2019314484A1 (en) | 2021-02-25 |
EP3830581A4 (en) | 2022-07-27 |
CN112789505B (en) | 2024-04-09 |
WO2020028722A9 (en) | 2020-04-09 |
CN112789505A (en) | 2021-05-11 |
US11479760B2 (en) | 2022-10-25 |
IL280442A (en) | 2021-03-01 |
EP3830581A1 (en) | 2021-06-09 |
US20210309975A1 (en) | 2021-10-07 |
KR20210049805A (en) | 2021-05-06 |
MX2021001065A (en) | 2021-06-23 |
JP2021532747A (en) | 2021-12-02 |
US20230193221A1 (en) | 2023-06-22 |
CA3107544A1 (en) | 2020-02-06 |
SG11202100725YA (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11479760B2 (en) | Biosynthetic platform for the production of cannabinoids and other prenylated compounds | |
US20230348866A1 (en) | Biosynthetic platform for the production of cannabinoids and other prenylated compounds | |
WO2006089898A1 (en) | Metabolically engineered cells for the production of resveratrol or an oligomeric or glycosidically-bound derivative thereof | |
EP3140409B1 (en) | Drimenol synthase and method for producing drimenol | |
US10822623B2 (en) | Synthetic biochemistry molecular purge valve module that maintain co-factor balance | |
CN114502734A (en) | Methods and cells for microbial production of phytocannabinoids and phytocannabinoid precursors | |
JP7487099B2 (en) | Pea (Pisum sativum) kaurene oxidase for highly efficient production of rebaudioside | |
CA3101424A1 (en) | Method for producing monoterpenoid compounds | |
AU2013227067A1 (en) | Hydrocarbon synthase gene, and use thereof | |
EP3368673A1 (en) | Compositions and methods for production of myrcene | |
US20200308612A1 (en) | Vetiver | |
CA3220078A1 (en) | Prenyltransferase variants with increased thermostability | |
US20180094281A1 (en) | Production of fragrant compounds | |
US20240076699A1 (en) | Biosynthesis of substituted compounds and cannabinoids | |
US20220243230A1 (en) | Bioconversion of 4-coumaric acid to resveratrol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19843397 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3107544 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021504498 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021001450 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019314484 Country of ref document: AU Date of ref document: 20190801 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019843397 Country of ref document: EP Effective date: 20210301 |
|
ENP | Entry into the national phase |
Ref document number: 112021001450 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210126 |